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1. SUMMARY 
 
In the overlapping areas of psychiatry and neurology, there are several disorders with 
motor symptoms that can be measured objectively to assess symptom severity or to 
understand pathophysiological mechanisms. Motor restlessness is an important but 
often poorly recognized and misdiagnosed symptom. 
 
Neuroleptic-induced akathisia (NIA) and restless legs syndrome (RLS) are 
hyperactive movement disorders, whereas attention deficit hyperactivity disorder 
(ADHD) and Asperger’s disorder are developmental disorders with prominent motor 
symptoms. Measuring motor activity by actometry (detects acceleration) is 
hypothesized to give abnormal findings in all of these disorders. In addition, an 
objective marker and a measure of symptom severity are needed for NIA and RLS. 
 
The main outcome parameter in this study was lower-limb activity during 30 min of 
rest in a standardized setting (controlled rest-activity). Fifteen schizophrenic patients 
with NIA, 15 antisocial personality disorder (ASP) patients with ADHD, 15 RLS and 
10 Asperger’s disorder patients, and 35 healthy controls were included. 
 
The increase of controlled rest-activity was manyfold (10-85x) and significant in all 
patient groups compared with healthy controls. It discriminated with no overlap the 
NIA and ASP/ADHD groups but not the RLS and Asperger groups from healthy 
controls. A significant decrease of activity to the level of healthy controls occurred in 
NIA patients during remission. All patient groups, except the RLS group, showed the 
rhythmic, episodic activity pattern previously reported in NIA. This was most readily 
seen in the NIA group. A pathognomonic periodic limb movement pattern at 5- to 90-
s intervals was found in RLS.  
 
The results demonstrate that rest-activity is abnormal in NIA, RLS, ASP/ADHD and 
Asperger’s disorder patients. Rest-activity measured by actometry can be used as a 
diagnostic marker and a measure of symptom severity in the two movement disorders 
(NIA and RLS), and it may be useful in symptom assessment and understanding of 
the pathophysiology of Asperger’s disorder and ADHD. Actometry enhances the 
objectivity of neuropsychiatric assessment. 
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2. INTRODUCTION 
 
2.1. Human motor activity 
 
Gravity and continuous motion appear to exist at enormous dimensions, like in 
clusters of galaxies, as well as at the microlevel of atoms, and everywhere in between. 
Human life, surrounded by an ever-moving universe, consists of movements both at 
the microlevel of  ions, molecules, genes and cells and at the macrolevel of vital 
functions, self-regulation, adaptation to environment and communication. The 
macrolevel movements are mediated by the activity of vegetatively innervated inner 
musculature or by cortically innervated skeletal muscles. Motor activity, a crucial sign 
and prerequisite of neural development, is observed very early in the life of the human 
foetus, right after the limbs have appeared by the 7th gestational week (Connolly and 
Forssberg 1997). 
 
A major product of the elaborate information processing in our brain is the 
modulation of contractile force in our skeletal muscles. The motor systems transform 
neural information into physical energy by issuing commands that are transmitted by 
brain stem and spinal cord to skeletal muscles. This is the reverse of the sensory 
systems, which transform physical energy into neural information. They supply a 
continuous flow of sensory information to the three hierarchical levels of motor 
control: the motor cortex, brain stem and spinal cord. These hierarchical mechanisms 
of motor control are integrated by several parallel mechanisms (Ghez 1991a). 
 
Human movements can be divided into three overlapping classes: voluntary 
movements, reflex responses and rhythmic motor patterns. Purposeful, voluntary 
movements are under cortical control, but their performance is also regulated by the 
lower levels, including the brain stem and spinal cord. The lower levels of the motor 
control system are capable of generating reflexes and rhythmic motor patterns. The 
reflexes are involuntary responses to a specific stimulus. The automatically sustained 
rhythmic motor patterns may be initiated and terminated voluntarily (Ghez 1991b).  
 
In addition to the hierarchical organization of the motor cortex, brain stem and spinal 
cord, other anatomical structures involved in the control of skeletal muscles comprise 
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the cerebellum, thalamus and basal ganglia. The basal ganglia consist of five 
interconnected nuclei: caudate nucleus, putamen, globus pallidus, subthalamic 
nucleus and substantia nigra. The basal ganglia and cerebellum control movements 
through the mediating actions of the brain stem and thalamic nuclei (Kelly and Dodd 
1991). The cerebellum directly regulates execution of movement, whereas the basal 
ganglia are involved in cognitive aspects of motor control (Cote and Crutcher 1991).  
 
2.2. Extrapyramidal system and its relevance for psychiatry 
 
The basal ganglia are often referred to as the extrapyramidal (EP) motor system, in 
contrast to the pyramidal motor system of corticospinal tracts. This nomenclature has 
been criticized because the pyramidal and EP systems are not independent but are 
extensively interconnected, and other parts of the brain are also involved in voluntary 
movements. The term EP system is still used, however, and the clinical motor 
manifestations of basal ganglia dysfunction are referred to as “extrapyramidal 
symptoms”. These can be classified as positive symptoms or signs, including 
involuntary movements and rigidity, and as negative symptoms, including 
bradykinesia and loss of postural reflexes resulting in imbalance (Lindsay et al. 1986). 
The role of basal ganglia in controlling movements includes several aspects, such as 
selective facilitation or suppression of movements, initiation of internally generated 
movements, execution of stereotyped movements and planning of complex motor 
strategies (Cote and Crutcher 1991, Canales et al. 2000).  
 
Recent anatomical studies have challenged the view that basal ganglia are solely 
concerned with motor control; they also seem to be involved in different aspects of 
behaviour and regulation of emotion (Middleton and Strick 2000). This is 
understandable since the basal ganglia have extensive connections with the 
association cortex and limbic structures (Cote and Crutcher 1991). The caudate 
nucleus and the putamen of basal ganglia together form the dorsal part of the striatum, 
also called the neostriatum, whereas limbic areas make up the ventral part of the 
striatum. The major components of the EP system comprise neostriatum, globus 
pallidus, substantia nigra, and the subthalamic nucleus (Borison and Diamond 1987). 
The connections between the amygdala and ventral striatum mediate limbic emotional 
and instinctive neural impulses to the motor systems of the basal ganglia (Graybiel 
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2001). The limbic autonomic and endocrine homeostatic regulation of the 
hypothalamus is mediated to the basal ganglia through the thalamus (Kupfermann 
1991).  
 
The great diversity of neurotransmitters in the basal ganglia, especially in the 
striatum, is probably needed for complex modulation of behaviours on the basis of 
sensorimotor, memory-related or conditional cues derived from the neocortex and 
limbic systems (Graybiel 2001). The transmitters found in the basal ganglia include at 
least dopamine (D), acetylcholine (ACh), 5-hydroxytryptamine (5-HT), noradrenaline 
(NA), gamma-aminobutyric acid (GABA), adenosine, homovanillic acid (HVA), 
glutamate, neurotensin, substance P, enkephalin, dynorphin and cholecystokinin 
(Lindsay et al. 1986, Borison and Diamond 1987, Cote and Crutcher 1991, Ferre 
1997, Huang and Hanson 1997, Reiner et al. 1999). Dopaminergic function in the 
dorsal striatum is involved in different aspects of motor behaviour than in the ventral 
striatum. Basal dopaminergic activity in dorsal striatum appears necessary for normal 
EP functions, such as execution of learned motor programmes, whereas stimulation of 
limbic dopaminergic transmission in the ventral striatum is essential for motivational 
motor behaviour (Di Chiara et al. 1992). 
 
Theories of neurotransmitter functions and interactions in basal ganglia are mostly 
based on animal studies. The interbalanced, reciprocal system of D and ACh is the 
best understood. An excess of D or depletion of ACh will result in chorea-type 
movement disorders, whereas an excess of ACh or depletion of D produces 
parkinsonism (Lindsay et al. 1986). In clinical pharmacology, the reciprocal system 
allows the antidopaminergic action in basal ganglia to be antagonized by 
anticholinergic actions (Pearl et al. 1976). EP movement disorders, however, involve 
more than simply a reciprocal balance between D and ACh (Borison and Diamond 
1987). 5-HT activation has an antagonistic effect on the dopaminergic EP function 
(Carter and Pycock 1979), while the excitatory glutamate system increases striatal 
dopaminergic function and thereby induces EP motor activation (Sacaan et al. 1992). 
An antagonistic interaction between D and adenosine seems to exist in the striatum 
(Ferre 1997).  
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The extrapyramidal (EP) system, responsible for integration of homeostatic, 
motivational and cognitive aspects of movement regulation, is of interest in psychiatry 
for several clinical reasons:  
 
1. Abnormal findings of basal ganglia pathology in several psychiatric disorders such 
as schizophrenia (Menon et al. 2001), autism (Jacobson et al. 1988, Sears et al. 1999), 
retarded depression (Martinot et al. 2001), obsessive compulsive disorder (OCD) 
(Rauch et al. 2001) and attention deficit hyperactivity disorder (ADHD) (Semrud-
Clikeman et al. 2000), and in alcoholic violent offenders (Kuikka et al. 1998).  
 
2. EP motor effects of psychoactive drugs, like the neuroleptic-induced movement 
disorders including parkinsonian symptoms, akathisia, tardive dyskinesia, and 
dystonias (Cunningham Owens 1999) and the psychostimulant-induced motor 
activation mediated by enhanced dopaminergic activity in the striatum (Graybiel et al. 
1990, Ferre 1997). 
 
 3. Psychiatric symptoms are commonly reported in diseases of the basal ganglia 
(Rosenblatt and Leroi 2000). Examples include anxiety, depression, flattened affect, 
psychomotor retardation and sleep disturbances which are described in Parkinson’s 
disease (Rosenblatt and Leroi 2000, Shulman et al. 2001); dysphoria, irritation,  
agitation, apathy and anxiety in Huntington’s disease (Paulsen et al. 2001); obsessive 
compulsive symptoms, other anxiety symptoms, depression, attention deficits and 
disruptive behaviour in Tourette’s disorder (Coffey and Park 1997), psychomotor 
retardation, amotivation, affective flattening and restlessness in striatal infarcts (Habib 
and Poncet 1988, Kumral et al. 1999); apathy, disinhibition, dysphoria and anxiety in 
progressive supranuclear palsy (Litvan et al. 1996) and incongruous behaviour, 
irritability and aggression in Wilson’s disease (Dening and Berrios 1989). Traumatic 
striatal injury may cause symptoms of OCD and ADHD (Hendler et al. 1999, 
Herskovits et al. 1999).  
 
The split between neurology and psychiatry about 100 years ago may have 
contributed to the lack of interest in  motor abnormalities in psychiatric disorders until 
the EP adverse effects of the newly discovered antipsychotic drugs of the 1950s drew 
attention to motor symptoms in psychotic patients (Beier 1997). Due to the typical 
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receptor action profile of conventional antipsychotic drugs, the EP adverse effects 
were first considered to be an essential sign of sufficient dosage for treatment 
response (Haase 1978). The drug-induced motor disturbances were so common that 
the possibility of primary EP dysfunction in psychotic disorders was dismissed for 
several decades (Beier 1997). Recent studies report that 17-21% of neuroleptic-naive 
schizophrenics show parkinsonian symptoms in clinical evaluation (Caligiuri et al. 
1993, Chatterjee et al. 1995). The affective flattening, psychomotor retardation and 
impairment of cognitive executive functions described in primary Parkinson’s disease 
(Marsh 2000, Rosenblatt and Leroi 2000) are also encompassed within schizophrenia 
symptomatology (American Psychiatric Association 2000, Jogems-Kosterman et al. 
2001).  
 
2.3. Abnormal motor function in neuropsychiatric disorders 
 
Neuropsychiatry is a discipline that seeks to understand the relationships between 
psychiatric symptoms, neurological symptoms and brain pathophysiology (Lyketsos 
2000). As the field of neuropsychiatric research and understanding grow (Lyketsos 
2000), the traditional distinction between “organic” and “functional” 
psychosyndromes is being questioned (Beier 1997). An increasing amount of 
neuropathology has been found behind the psychiatric disorders classified in the 4th 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
(American Psychiatric Association 2000). The psychiatric classification system also 
includes primarily neurological diseases, such as different types of dementia, of an 
identified organic aetiology with predominant neurological and neurocognitive 
symptoms. At the other end of the continuum are disorders considered to be primarily 
psychogenic or functional (Beier 1997), and between the two extremes is a large 
number of neuropsychiatric disorders with neurological signs and some evidence of 
organic neuropathology, but in which the pathophysiological mechanisms remain 
unclear. The motor disturbances in psychiatric disorders are obvious clinical signs of 
brain organic pathophysiology (Beier 1997). Studies on abnormal motor function are 
useful in constructing pathophysiological hypotheses and may benefit the clinical 
assessment of neuropsychiatric disorders.  
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2.3.1 Neurological soft signs, extrapyramidal symptoms and stereotypies 
 
Motor abnormalities are studied, for example, in schizophrenia, autistic disorders and 
ADHD, all of which are considered neurodevelopmental disorders (Weinberger 1995, 
Taylor 1999, American Psychiatric Association 2000, Tanguay 2000). Minor motor 
abnormalities, called “soft signs”, are commonly encountered in each of these 
disorders (Jones and Prior 1985, Aronowitz et al. 1994, Flashman et al. 1996). While 
the clinical significance of neurological soft signs (NSS) is ambiguous, they are 
widely regarded as an indicator of non-specific brain damage, although subcortical 
structures like basal ganglia have been speculated to be associated with them 
(Kennard 1960). The NSS include abnormalities in gait, balance, laterality, motor co-
ordination and integrative sensorimotor functions (Krebs et al. 2000). The term “soft 
sign” has been criticized for having ambiguous boundaries (Sanders and Keshavan 
1998). By definition, soft signs are neurological abnormalities that are not readily 
localizable to a specific brain region, while “hard signs”, or “major neurological 
signs”, such as reflex asymmetry, provide some indication of the underlying brain 
systems or regions affected (Sanders and Keshavan 1998).  
 
Though the discriminative value of motor co-ordination, motor intergration and 
sensory integration factors of NSS is good, there is overlap between the NSS factor of 
involuntary movements and EP symptoms. Thus, this factor needs careful 
interpretation when neuroleptic-treated patients are examined (Krebs et al. 2000). 
Single items from EP symptom rating scales, such as glabellar reflex, tremor and 
rigidity, are also included in validated NSS examinations (Buchanan and Heinrichs 
1989, Krebs et al. 2000). Some researchers report  tremor, rigidity and bradykinesia in 
neuroleptic-naive schizophrenics as idiopathic EP symptoms and signs rather than as 
NSS (Caligiuri et al. 1993, Chatterjee et al. 1995) and others exclude them from the 
analysis of NSS (Flashman et al. 1996, Smith et al. 1999).  
 
Stereotypies are involuntary, co-ordinated, patterned, repetitive, rhythmic and 
purposeless movements, which are encountered in tardive dyskinesia, akathisia, 
schizophrenia, autism, ADHD, OCD and Tourette’s disorder (Tan et al. 1997). The 
dopaminergic system in basal ganglia is assumed to be involved in production of 
stereotypies (Tan et al. 1997). The distinction between complex tics and stereotypies 
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is difficult and sometimes may even be artificial (Stern and Robertson 1997, Tan et al. 
1997), although some differentiating features have been described:  stereotypies are 
characterized by less distress and weaker association with psychosocial influence than 
tics (Stern and Robertson 1997). 
 
2.3.2. Schizophrenia 
 
Both soft signs and hard signs of nearly all functional domains are increased in 
schizophrenia, the subdomains of motor co-ordination and involuntary movements 
being the most prominent (Ismail et al. 1998). Because NSS are an intrinsic part of 
schizophrenia (Browne et al. 2000), a standardized neurological assessment method 
has been validated for them (Krebs et al. 2000). The NSS are associated with 
treatment resistance and negative symptoms in schizophrenia (Smith et al. 1999) 
defined as affective flattening, alogia, avolition, anhedonia and reduced attention 
(Andreasen 1989). NSS are also correlated with poor neuropsychological performance 
on motor tasks in test batteries, but do not correlate with general intellectual ability in 
neuropsychological assessment (Flashman et al. 1996). NSS are also present in never-
medicated schizophrenics, but its prevalence is reported to be higher in neuroleptic-
treated than in never-medicated patients (Gupta et al. 1995). Both soft signs and hard 
signs seem to be part of the disease process rather than a medication effect (Gupta et 
al. 1995, Ismail et al. 1998), although the neuroleptic medication may increase the 
prevalence of NSS. The interpretation of the medication effects on NSS in these 
studies (Gupta et al. 1995, Ismail et al. 1998) can be confounded by the overlap 
between assessed EP symptoms and NSS.   
 
The idiopathic EP symptoms, similarly to NSS (Gupta et al. 1995, Smith et al. 1999), 
are related to negative symptoms, poor treatment response and susceptibility to drug-
induced EP adverse effects in schizophrenia (Chatterjee et al. 1995). Rigidity and 
bradykinesia have been observed in neuroleptic-naïve patients in clinical evaluation 
(Caligiuri et al. 1993, Chatterjee et al. 1995), but instrumental examination has also 
demonstrated subclinical tremor in them (Caligiuri et al. 1993). Spontaneous 
dyskinesia, phenomenologically identical to neuroleptic-induced tardive dyskinesia, is 
also reported to exist in neuroleptic-naïve schizophrenics (Fenton et al. 1997, Fenton 
2000). The prevalence of spontaneous dyskinesia seems to be associated with the age 
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of patients (Fenton 2000), being significantly higher in schizophrenia patients as 
compared with other neuroleptic-naïve psychiatric patients. The non-schizophrenic 
patients most often affected are those diagnosed with a schizophrenia-spectrum 
disorder, or bipolar disorder (Fenton et al. 1997). The presentation of idiopathic EP 
symptoms in schizophrenia may be related to low baseline dopaminergic activity in 
subcortical areas, including the basal ganglia, which has been suggested to be a 
pathophysiological prerequisite for dopaminergic sensitization leading to full 
symptomatology (Glenthöj and Hemmingsen 1997). Thus, the conventional 
neuroleptics treat the positive psychotic symptoms at the cost of further basal 
dopaminergic hypofunction (Glenthöj and Hemmingsen 1999). 
  
Catatonic motor behaviours are classified as characteristic positive symptoms of 
schizophrenia including catatonic stupor, -rigidity, -negativism, -posturing and -
excitement (American Psychiatric Association 2000). Motor poverty, dyskinetic 
symptoms and stereotypies are more strongly associated with schizophrenia than with 
other psychotic disorders (Peralta and Cuesta 2001). The prevalence of motor 
symptoms seems to decrease in hospitalized patients while the psychotic episode is 
treated (Peralta and Cuesta 2001). The reduced psychomotor activity related to 
negative symptoms of schizophrenia is connected with EP symptoms in assessment 
by rating scales due to an overlap of symptom descriptions. Objective EP signs are 
more difficult to differentiate from negative symptoms by assessment scales than 
subjective EP symptoms (Dollfus et al. 2000).  
 
2.3.3. Neuroleptic-induced movement disorders 
 
The neuroleptic-induced EP symptoms include parkinsonian symptoms, akathisia, 
tardive dyskinesia (TD), and acute or tardive dystonia (Cunningham Owens 1999), 
which are defined in DSM-IV (American Psychiatric Association 2000). This 
classification also includes neuroleptic malignant syndrome in the category of 
medication-induced movement disorders, although autonomic symptoms, 
disturbances of consciousness, and possible impairment of vital functions are 
clinically more relevant than the concomitant muscle rigidity, which may resemble 
catatonia. Addition of the category medication-induced movement disorders not 
otherwise specified in DSM-IV, acknowledges that drugs other than neuroleptics can 
 19 
also cause comparable EP movement disorders (American Psychiatric Association 
1994, Leo 1996).  
 
Akathisia is a state of motor restlessness with subjective feelings of inner restlessness 
(Sachdev 1995a); for further description, see section 3.1. TD is characterized by 
abnormal, involuntary movements, which are typically choreiform, choreoathetoid or 
rhythmic and stereotyped (American Psychiatric Association 2000). The reported 
increase of TD with age and years of neuroleptic exposure may be in part accountable 
for the age-related increase of spontaneous dyskinesia misinterpreted as neuroleptic-
induced dyskinesia (Khot and Wyatt 1991). Neuroleptic-induced dystonic movements 
include abnormal positioning or spasms of the muscles in the affected body part 
(American Psychiatric Association 2000). 
 
The iatrogenic, neuroleptic-induced parkinsonian symptoms are bradykinesia or 
hypokinesia, rigidity and tremor. The motor symptoms in neuroleptic-induced 
parkinsonism, known also as secondary parkinsonism, are slightly different from 
those in primary Parkinson’s disease (PD) (Cunningham Owens 1999): bradykinesia 
is a dominating symptom in secondary parkinsonism, whereas in PD it is essential 
mainly in the upper body. Rigidity is more severe and progressive in PD than in 
secondary parkinsonism, in which it is often mild or moderate, typically requiring 
reinforcement to be detected. Resting tremor is present in the majority of PD patients, 
while it is a rare, late manifestation of secondary parkinsonism. Postural tremor, by 
contrast, is a common, early manifestation of secondary parkinsonism. Furthermore, 
the motor symptoms seem to be more lateralized in PD than in secondary 
parkinsonism. 
 
2.3.4. Restless legs syndrome (RLS) 
 
The category of dyssomnias in the psychiatric classification of DSM-IV also includes 
idiopathic RLS (for clinical description, see section 3.2.), a movement and sleep 
disorder (Amar 2001), which has often been misdiagnosed as a psychiatric disorder 
because of its secondary effects on sleep and mood (Chokroverty and Jankovic 1999). 
Today, it is considered to be an independent neurological disorder (Winkelmann 
1999). The most studied motor abnormalities related to RLS are periodic limb 
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movements in sleep (PLMS), which are common but non-essential features of RLS 
(IRLSSG 1995). Motor restlessness, one of the key features of RLS (IRLSSG 1995, 
Table 2), includes both a component of involuntary periodic limb movements (PLM) 
and a component of voluntary movements in response to sensory symptoms 
(Montplaisir et al. 1998). The motor restlessness and subjective discomfort related to 
RLS are modulated by circadian rhythm, being maximal in the night-time and 
minimal in the daytime (Hening et al. 1999b). Both RLS and nocturnal akathisia are 
claimed to be common sleep disturbances in Parkinson’s disease (Stocchi et al. 2000), 
but there seems to be some overlap in their descriptions (Sachdev 1995a). Moreover, 
a recent clinical study shows that the motor restlessness in Parkinson’s disease 
patients seems to be related to akathisia rather than RLS when standard diagnostic 
criteria are applied (Tan et al. 2002).  
 
2.3.5. Attention deficit hyperactivity disorder 
 
NSS in low-birthweight children seem to predispose them to attention deficits 
(Breslau et al. 2000). They can be helpful in differentiating the children at risk for 
developing ADHD (Vallee and Pandit 1991). An increased presentation of NSS 
appears to be related to ADHD with or without a comorbid conduct disorder but not 
to conduct disorder alone (Aronowitz et al. 1994). Hyperactivity is correlated with 
inattention in ADHD (Dane et al. 2000), but it is considered to be a primary feature of 
ADHD, instead of merely being a secondary effect of inattention (Porrino et al. 
1983a). The impairment of motor skills does not explain the hyperactivity detected 
(Porrino et al. 1983a). Motor hyperactivity is present in ADHD independent of 
subtype and seems to be related to situations demanding self-regulation (Dane et al. 
2000). It is the most discriminative feature of ADHD in comparison with other 
psychiatric disorders (Halperin et al. 1992). Psychostimulants reduce motor 
hyperactivity (Porrino et al. 1983b), but during medication ADHD children are 
vulnerable to developing tics (Varley et al. 2001). 
 
2.3.6. Autistic spectrum disorders 
 
Motor disturbances, including NSS, movement disorders and stereotypies, are 
characteristic of autism (Vilensky et al. 1981, Jones and Prior 1985, Gillberg 1995, 
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Brasic 1999). Movement disturbances may be essential for the core features of autism 
because they can have a profound effect on a person’s ability to regulate movement to 
effectively communicate, relate and participate with others (Leary and Hill 1996). The 
motor impairment in autistic children is more severe than that of children with 
learning disabilities (Hughes 1996). Asperger’s disorder patients appear to have more 
sensory-motor dysfunction, especially in maintaining their balance, than patients with 
high-functioning autism at the same cognitive level (Iwanaga et al. 2000). Even 
Asperger’s disorder patients with exceptionally high verbal intelligence may have 
considerable motor impairment in the form of numerous soft signs and motor tics 
(Nass and Gutman 1997). The increased caudate volume in high-functioning autism 
seems to be positively associated with motor mannerisms (Sears et al. 1999). 
 
Basal ganglia have been suggested to be responsible for the force-control component 
of clumsiness, reported in Asperger’s disorder (Smith 2000) and for parkinsonian-
type disturbances of gait, detected in autism (Vilensky et al. 1981). Both autistic and 
parkinsonian patients display bradykinetic and rigid gait detected as shortened stride 
lengths, elongated stance phases and reduced joint flexions (Vilensky et al. 1981). 
 
2.3.7. Other disorders 
 
Tourette’s disorder, which shows some comorbidity with OCD-, ADHD- and autistic 
features (Baron-Cohen et al. 1999, Kadesjö and Gillberg 2000), is characterized by 
involuntary motor and vocal tics (American Psychiatric Association 2000). Tics and 
Tourette’s disorder are part of the same spectrum of disorders (Gillberg 1998a). NSS 
are common in Tourette’s disorder (Semerci 2000). Repetitive, stereotyped 
behaviours typical of both Tourette’s disorder and OCD may be related to striato-
thalamic dysfunction in these disorders (Rauch et al. 2001). 
 
In OCD, the presentation of high NSS scores is associated with volumetric reduction 
of brain tissue (Stein et al. 1993a). The severity of OCD symptoms and 
neuropsychological impairment are correlated with NSS (Bolton et al. 2000). An 
increased amount of NSS may also be found in some other psychiatric disorders 
(Stein et al. 1993b, Gurvits et al. 2000), probably indicating a general 
neuropsychiatric vulnerability related to non-specific brain damage (Kennard 1960).  
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2.3.8. Pathophysiological considerations 
  
Some evidence exists for dopaminergic and basal ganglia pathophysiology in several  
neuropsychiatric disorders with abnormal motor function, including schizophrenia 
(Glenthöj and  Hemmingsen 1997, Menon et al. 2001), autism (Jacobson et al. 1988, 
Ernst et al. 1997, Sears et al. 1999), ADHD (Krause et al. 2000), RLS (Turjanski et al. 
1999, Ruottinen et al. 2000), OCD (Lucey et al. 1997, Billet et al. 1998) and 
Tourette’s disorder (Malison et al. 1995, Ernst et al. 1999), but obviously other 
mechanisms are also involved. The presentation of NSS has not been connected to 
any specific brain region (Sanders and Keshavan 1998). The evidence for 
dysfunctional frontostriatal circuits in developmental neuropsychiatric disorders is 
increasing (Gillberg 1998a). Even EP movement disorders may have origins other 
than basal ganglia, such as the limbic and motor cortices, which seem to be involved 
in the pathophysiology of NIA (Ohashi et al. 1998), and the circuits connecting the 
cortex, thalamus, basal ganglia and cerebellum, which are suggested to be involved in 
the pathogenesis of involuntary movements and hyperkinesias (Rice and Thompson 
2001). 
 
2.4. Measuring motor activity in neuropsychiatric disorders  
 
2.4.1. Methods 
 
Human motor activity can be measured directly as gross and fine three-dimensional 
movements by accelerometric methods and as electric activity of motor units by 
electromyography (EMG) and its applications. Actometry and actigraphy are used in 
the literature as synonyms for recording methods based on accelerometric sensors. 
Accelerometric applications include both old mechanical and more modern 
piezoelectric, computerized detectors, and they all react to acceleration signals 
produced by body movements. The modulation, integration and recording of the 
signal are varied, as is the output of the data in different types of accelerometric 
methods and their commercial applications. The ambulatory monitors in 
accelerometric methods are typically attached to the limbs of the patient in a wrist-
watch manner. EMG electrodes measure electrical signals emitted during muscle 
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contractions. Surface electrodes can detect activity from large superficial muscles, but 
the more invasive needle or wire electrodes are needed to discriminate activity from 
smaller deep muscles. The disturbing effect of EMG electrodes on normal moving of 
the subject has been studied in neurological child patients (Young et al. 1989), and 
expectedly, the surface electrodes caused less disturbance.  
 
Angular joint movements can be measured by electro-goniometers, which record the 
relative orientation of two bases connected by an elastic beam (Legnani et al. 2000). 
The different versions of electro-goniometers include strain gauges (Legnani et al. 
2000). Strain gauges are also a component of a force transducer, which measures 
muscle rigidity (Caligiuri 1994) defined as the ratio of changing muscle force to 
changing muscle length. A force transducer is attached to the limb of the patient and 
the external force applied by the examiner to displace the patient’s limb is transduced 
along with rotation (Caligiuri 1994). Other indirect methods of measuring motor 
activity are, for example,  ultrasonographic movement counters (May et al. 1983, Hoff 
et al. 1999), digital video camera movement analysis (Nilsson et al. 1996), 
photodetectors (May et al. 1983, Hoff et al. 1999), posturography (Bloem et al. 1998, 
Lanska 2001), pedometers (Dale et al. 2002) and static charge sensitive beds (SCSB), 
which record the changes of electric potentials in the mattress of the bed induced by 
body movements (Alihanka and Vaahtoranta 1979, Kronholm et al. 1993). 
 
In addition to measuring body movements and motor activity of the muscles, other 
dimensions of motor functions, such as central magnetic or electric potentials, 
corticospinal excitability and peripheral conduction velocity (Rossini and Mauguire 
1990) are measured in neuropsychiatry. Methods of assessing human motor activity 
also include systematic, direct observations and self-report questionnaires (Dale et al. 
2002). Measuring movements and motor activity is common in clinical 
neurophysiology, neurology and sleep medicine, but it has also been utilized in 
psychiatry, geriatrics, orthopaedics, traumatology, physiatrics, occupational medicine 
and sports medicine (Tuisku et al. 2002a). 
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2.4.2. Clinical relevance 
 
Developing objective methods to measure various motion characteristics for studying 
the pathophysiology of movement disorders and their response to treatment is 
essential (Jankovic and Frost 1981). Certain neuropsychiatric disorders with 
prominent motor symptoms have been a focus of movement analysis. Objective 
quantification of the frequency and intensity of tics in Tourette’s disorder is 
considered to be essential for diagnostic purposes, evaluation of treatment response 
and increasing understanding of the pathophysiology of the disease (Tulen et al. 
2001). An accelerometric method has been developed for these purposes (Tulen et al. 
2001). Instrumental analysis of the quality of motor activity may sometimes be useful 
in differentiating between neurological and psychiatric aetiologies for motor 
symptoms (Knutsson and Martensson 1985). Measuring the diurnal activity and 
exploring the activity rhythm may aid in subtyping some psychiatric disorders 
(Teicher 1995). 
 
Elevated activity levels have been detected by accelerometric studies in such 
psychiatric disorders as ADHD, mania and agitated depression, whereas attenuated 
activity has been found in bipolar depression and seasonal depression, in which a 
significant degree of circadian dysregulation appears to be persent (Teicher 1995). 
The circadian dysregulation is pathophysiologically interesting, as it seems to 
normalize in seasonal depression during an antidepressive treatment response to 
bright light therapy (Partonen et al. 1993). Accelerometric studies also show 
attenuation of circadian rhythm in major depression, and the antidepressant drugs 
have been hypothesized to work by restoring the circadian rhythm (Teicher 1995). 
Ambulatory accelerometry has also been validated for quantifying motor activity for 
the purpose of psychopharmacological studies (Tulen et al. 1997). In elderly 
schizophrenia patients, a higher dosage of neuroleptics and elevated levels of EP 
symptoms were associated with flattening of circadian activity rhythm measured by 
actigraphy (Martin et al. 2001).  
 
The iatrogenic, drug-induced movement disorders have traditionally been evaluated 
by rating scales, which are based on clinician’s subjective judgements (Simpson and 
Angus 1970, Barnes 1989, Caligiuri 1994, Cunningham Owens 1999) and often fail to 
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detect small but significant changes in motor function (Jankovic and Frost 1981). 
Furthermore, some rating scales have unsatisfactory statistical properties 
(Cunningham Owens 1999, Loonen et al. 2000) or are unsuitable for drug-induced EP 
symptoms because of their item selection (Cunningham Owens 1999). Measuring 
motor activity offers a window for objective qualitative and quantitative analyses of 
EP adverse effects, besides being helpful in diagnosing them. Drug-induced EP 
symptoms are generally underdiagnosed in clinical practice (Weiden et al. 1987, 
Hansen et al. 1992). Early detection of motor symptoms also supports identifying 
concomitant, more hidden and underdiagnosed emotional and cognitive components 
of EP adverse effects. Early diagnosis and treatment of EP symptoms is important to 
prevent their chronic development (Cunningham Owens 1999) and harmful clinical 
effects (Lindström 1994, Newcomer et al. 1994, Owens 1996, Cunningham Owens 
1999).  
 
Clinical neurophysiological methods, such as EMG, produce detailed and accurate 
information on motor activity, but their disadvantage is that they are non-naturalistic 
and even invasive. In general, what we gain in objectivity and accuracy with 
instrumental measuring, we lose in relating to the patient’s daily life and practical 
significance. The most naturalistic instrumental assessment methods of motor activity 
are accelerometric, ambulatory monitors. Because their disturbing effect on normal 
moving of the subject is minimal and no laboratory assessment is needed, patient 
compliance is expected to be good and actometric studies cost-effective based on 
sleep studies (Kazenwadel et al. 1995). 
 
In sleep studies, motor activity is measured to detect pathological movement patterns 
in legs, quantify overall movement activity during sleep, diagnose sleep disorders and 
define the sleep stage in polysomnography, examine the circadian rhythm, and grossly 
differentiate between sleep and wakefulness (Rechtschaffen and Kales 1968, Sadeh et 
al. 1989, Mills et al. 1993, Sadeh et al. 1995, Chokroverty 2000). 
 
2.4.3. Drug-induced extrapyramidal symptoms 
 
All motor EP symptoms can be measured by objective instruments. Parkinsonian 
symptoms have been studied more than the others, initially because of the clinical 
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importance of primary Parkinson’s disease. The earliest documented study, in which 
an electromechanical transducer was used to record rigidity, was reported in 1959 
(Caligiuri 1994). Since then, this method has been further developed and applied to 
neuroleptic-induced EP rigidity (Caligiuri 1994, Caligiuri et al. 1998). In general, the 
instrumental methods used in primary parkinsonism can be applied to drug-induced 
parkinsonism. In primary parkinsonism, the transducer has been used to study the 
motor components of akinesia (Benecke et al. 1986), and actometry has been used to 
quantify the daily motor activity and detect the increase of activity in response to 
treatment in hypokinetic patients (Fujikane et al. 1997). Accelerometric methods have 
been developed to identify and monitor the qualities of parkinsonian tremor (Frost and 
Jankovic 1981, van Someren et al. 1998).   
 
Neuroleptic-induced tremor has been analysed qualitatively and quantitatively by 
EMG recording of ankle antagonist muscles (Bathien et al. 1984). It has also been 
measured with accelerometric applications including tremography (Alpert et al. 1976, 
Collins et al. 1979, May et al. 1983). When developing neuroleptic-induced tremor, 
the frequency of the tremor in accelerometry seems to be a more significant 
pathological sign than the amplitude (Collins et al. 1979), although a decrease of 
amplitude has been observed in EMG as part of the treatment response to 
anticholinergic medication (Bathien et al. 1984). Accelerometric decrease of tremor 
frequency from the level of physiological tremor (10 Hz) seems to be a preceding sign 
of developing EP symptoms (Collins et al. 1979). 
 
Instrumental methods can also be helpful in differential diagnosis of different types of 
tremor. In addition to detecting the amplitude and frequency of tremor, accelerometry 
has been used to analyse the smoothness of motion and the waveform of acceleration 
during a voluntary movement of a patient with tremor (Jankovic and Frost 1981). 
Quantitative computerized tremor analysis by EMG and accelerometry have been 
applied to differentiate between normal physiological tremor and essential tremor 
(Louis and Pullman 2001) and to monitor long-term age-related changes in tremor 
frequency (Elble 2000). These tremors of higher frequencies may be difficult to 
discriminate by instrumental measuring from the postural component of parkinsonian 
tremor of frequency range 8-10 Hz. The frequency range of clinically well-identified 
rest-tremor in parkinsonism is, however, lower, 4-6 Hz (Cunningham Owens 1999). 
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The typical tremor frequency range of parkinsonism (above 4 Hz) is higher, and thus, 
distinguishable from the frequency range of NIA activity, which is below 4 Hz 
(Braude et al. 1984, Rapoport et al. 1994, Cunningham et al. 1996).  
 
 
The lower limb movement patterns in NIA have been studied qualitatively by EMG 
(Lipinski et al. 1991, Cunningham et al. 1996) and accelerometry (Braude et al. 1984, 
Rapoport et al. 1994). EMG reveals continuous rhythmic bursts of lower limb activity 
of 0.5-3 Hz in episodes of 1.7 min in average duration (Lipinski et al. 1991, Walters et 
al. 1991, Cunningham et al. 1996). An EMG marker of NIA was established when the 
duration of uninterrupted rhythmic lower limb activity of 0.5-3 Hz exceeded 10 s, and 
this marker differentiated the NIA patients from neuroleptic-treated patients without 
NIA with a sensitivity of 69% and a specificity of 70% (Cunningham et al. 1996). The 
presentation of NIA activity was positively correlated with the relative neuroleptic 
dose (Cunningham et al. 1996). Rhythmic lower limb activity of frequencies below 4 
Hz has also been demonstrated by accelerometry in NIA patients (Braude et al. 1984, 
Rapoport et al. 1994). Quantification of diurnal motor activity in NIA has been 
performed by actometry (Gardos et al. 1992, Poyurovsky et al. 2000), demonstrating 
an overall increase of diurnal motor activity in NIA patients and a trend to specific 
periodicity (Poyurovsky et al. 2000).  
 
EMG is the most commonly used method in instrumental quantification of TD and 
other forms of dyskinesia. The most prevalent forms of dyskinesia are the neuroleptic-
induced TD, levodopa-induced dyskinesia and dyskinesias related to Huntington’s 
disease (Hoff et al. 1999). EMG activity in TD has been classified into three types: 
rhythmic clonic (1-3 Hz) and tonic (below 1 Hz) bursts, and irregular bursts of 
varying length, frequency and amplitude. Unlike in tremor, there is no reciprocal co-
ordination between agonist and antagonist muscle activities in TD (Bathien et al. 
1984). The spreading, distribution and amplitude of dyskinetic activity has been 
analysed in detail by a combination of video and EMG recording in levodopa-induced 
dyskinesia (Marconi et al. 1994). Other objective techniques of quantifying dyskinetic 
movements include, for example, digital video recording movement analysis, force 
transducer, photodetectors and ultrasound counter (May et al. 1983, Nilsson et al. 
1996, Hoff et al. 1999). The current instrumental methods of assessing TD require a 
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laboratory setting and provide only a momentary assessment of symptom severity. An 
accelerometric method for quantification of the spontaneous movements of TD 
patients has been presented by Fann et al. (1977). The recording sites were both 
hands, legs and the chin of the patient.  Ambulatory accelerometry allowing a 
naturalistic long-term home-recording has been suggested as a possible solution for 
these methodological problems (Hoff et al. 1999). 
  
The electromyographical properties of primary dystonia have been studied in detail 
(Pullman et al. 1996), and an EMG method for quantitative and qualitative evaluation 
of dystonic muscle has been developed for clinical use (Dressler 2000). One case 
report outlines the possible usefulness of EMG analysis in differential diagnosis of 
neuroleptic-induced tardive dystonia (Jyoichi et al. 1989).  
 
A major difficulty in diagnosis and monitoring of EP adverse effects, and thus, also in 
research and evaluation of new antipsychotic drugs, is that EP symptoms are difficult 
to measure. Instrumental techniques have been developed for objective evaluation of 
EP adverse effects, but their impracticality has limited their clinical use (May et al. 
1983). The instrumental assessment of pre-existing motor abnormalities has predictive 
value for the prognosis of developing drug-induced EP symptoms (Collins et al. 1979, 
Caligiuri et al. 1998). The instrumental measurements of motor activity used in EP 
symptoms are presented in Table 1. 
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Table 1: Instrumental techniques of assessing neuroleptic-induced movement 
disorders and their usefulness. 
 
 Accelerometric 
methods 
Electromyography Transducer 
    
Parkinsonism +++ ++ +++ 
Akathisia +++ ++ - 
Dystonias - + - 
Tardive dyskinesia + ++ - 
 
- : not reported 
+  : at least one report 
++ : several studies: diagnostic significance  
+++ : valid for clinical practice: supports diagnostics and monitoring 
 
3.  REVIEW 
 
3.1. Neuroleptic-induced akathisia (NIA) 
 
Akathisia is characterized by an unpleasant, distressing inner restlessness, the urge to 
move and restless movements (Sachdev 1995a, Cunningham Owens 1999). The word 
”akathisia” is of Greek origin and  literally means ”not to sit”, referring directly to the 
inability to sit still which has been observed in akathisia patients and is experienced 
by themselves. Akathisia was first regarded as a non-organic psychiatric disorder 
before it was mentioned as an organic, EP symptom when described in association 
with idiopathic and post-encephalitic parkinsonism in 1923 (Adler et al. 1989, 
Sachdev 1995a). Akathisia is estimated to be present in 25-50% of patients with 
idiopathic Parkinson’s disease in the absence of neuroleptic medication (Lang and 
Johnson 1987, Witjas et al. 2002). The first case of drug-induced akathisia (DIA) was 
reported in 1947 as an adverse effect of promethazine (Sachdev 1995a, Chung and 
Chiu 1996). After the invention of neuroleptic drugs, the term akathisia has come to 
be used synonymously with drug-induced akathisia (DIA) (Sachdev 1995). The 
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prevalence of akathisia is about 20-30% in patients on long-term neuroleptic 
treatment, but the current incidence is expected to be lower than in the past, as more 
atypical (novel) antipsychotics are used first-line (Chung and Chiu 1996).  
 
The drugs most frequently implicated in the pathogenesis of akathisia are those which 
either directly or indirectly interfere with dopaminergic functions, and it is reasonable 
to conclude that this is a fundamental mechanism underlying development of the 
disorder (Cunningham Owens 1999). DIA is best known as an important EP adverse 
effect of D2 blocking conventional antipsychotics, but several other drugs with 
antidopaminergic activity also exist which can cause acute DIA, for example, lithium, 
buspirone, calcium channel antagonists (Sachdev 1994) and antiemetics (Ganzini et 
al. 1993, Foster et al. 1996). Pharmacological studies suggest that the serotonergic, 
adrenergic and opioid systems are involved in the pathophysiology of akathisia, either 
directly or through the dopamine system (Chung and Chiu 1996). DIA caused by 
selective serotonin reuptake inhibitors may be related to an inhibitory effect of 
serotonergic input to dopaminergic systems (Leo 1996). A noradrenergic mechanism 
is supported by the observations of Zubenko et al. (1987), who reported akathisia 
induced by tricyclic antidepressants and relieved by a beta-adrenergic blocker, 
propranolol. DIA may be involved in the pathophysiological mechanisms of suicidal 
ideation and behaviour precipitated by antidepressive drugs (Teicher et al. 1993). 
 
Neuroleptic-induced akathisia (NIA) is a common but underdiagnosed and easily 
misdiagnosed adverse effect of conventional antipsychotics (Barnes and McPhillips 
1999). Early diagnosis is essential because akathisia often causes marked distress to 
the patient and may progress, become chronic or be related to a higher risk of 
developing tardive dyskinesia (Munetz and Cornes 1983). It may also predispose to 
physical aggression and threatening behaviour (Ratey and Gordon 1993, Stubbs et al. 
2000), suicidal behaviour (Drake and Ehrlich 1985, Siris 2001), insomnia (Goldstein 
2000), poor drug compliance (Van Putten 1974, Lindström 1994, Goldstein 2000), 
poor treatment response (Newcomer et al. 1994) and exacerbations of psychosis (Van 
Putten 1975). Furthermore, there is some evidence of the disruptive effect of NIA on 
spatial working memory, which is probably mediated by the increased distractability 
in NIA (McCartan et al. 2001).  
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The lower risk of developing akathisia and other EP symptoms with novel 
antipsychotics than with conventional antipsychotics (Miller et al. 1998, Goldstein 
2000, Voruganti et al. 2000) is hypothesized to be related to the lower D2 receptor 
occupancy with commensurately higher 5-HT2 occupancy and limbic selectivity 
(Arnt and Skarsfeldt 1998, Goldstein 2000) of novel antipsychotics. In addition to 
these common features, most novel antipsychotics have high relative affinity for D1 
receptors, alpha 2 adrenoreceptors and histamine 1 receptors (Arnt and Skarsfeldt 
1998). Fewer EP adverse effects with clozapine and quetiapine may be due to loose 
binding of these drugs at D2 receptors, while risperidone and olanzapine may cause 
EP symptoms at higher doses (Goldstein 2000). In comparison, risperidone produces 
EP symptom levels intermediate between clozapine and conventional antipsychotics 
(Arnt and Skarsfeldt 1998, Miller et al. 1998), and higher than olanzapine (Tran et al. 
1997, Arnt and Skarsfeldt 1998, Bobes et al. 2002). The EP adverse effect of 
risperidone, however, is highly dose-dependent; at higher dosages, the risk appears to 
be equal to that of conventional antipsychotics, while at lowest treatment dosages, the 
risk is reported to be relatively low (Tarsy et al. 2002).   
 
Positron emission tomography (PET) findings indicate that neuroleptic-induced EP 
syndromes, including NIA, are related to the degree of neuroleptic D2 receptor 
occupancy in the nucleus caudatus and nucleus putamen of the basal ganglia (Farde et 
al. 1992). The theory concerning involvement of mesocortical dopaminergic tracts in 
pathophysiology of NIA is mainly supported by animal studies (Marsden and Jenner 
1980, Cunningham Owens 1999). While the blockade of D receptors in the striatum 
produces inhibition of locomotor activity, the reverse occurs on blockade of 
mesocortical dopaminergic systems, supporting their role in the pathogenesis of the 
hyperkinetic symptoms of akathisia (Marsden and Jenner 1980). Some limbic cortical 
structures involved in the pathophysiology of NIA according to an 
immunohistochemical animal study (Ohashi et al. 1998) can have a central role in 
mediating the subjective dysphoria related to akathisia. 
 
The recommended initial interventions to treat NIA are dose reduction of the 
antipsychotic medication or switching it to another; the most recommended atypical 
antipsychotics are clozapine, olanzapine and quetiapine (Taylor et al. 2001). When 
this is not effective or possible, either betablocker (propranolol) or an anticholinergic 
 32 
drug is added to the treatment, but the latter may be effective only in patients with 
comorbid drug-induced parkinsonian symptoms (Fleischhacker et al. 1990, American 
Psychiatric Association 1997, Taylor et al. 2001). Propranolol is suggested to be the 
most effective treatment according to research data, but comparisons between 
treatment options are still needed (Adler et al. 1989, Fleischhacker et al.1990, 
American Psychiatric Association 1997, Poyurovsky and Weizman 2001). Secondary 
options include benzodiazepines, cyproheptadine and clonidine (Taylor et al. 2001). 
Also low-dose mianserine has proved effective in treatment of NIA. The treatment 
response is probably mediated by increase of the 5-HT2/D2 receptor occupancy ratio 
(Poyurovsky et al. 1999). Other serotonergic agents may prove useful in the future 
(Poyurovsky and Weizman 2001).    
 
NIA and other EP adverse effects can be prevented by choosing atypical 
antipsychotics, by careful patient monitoring and adequate patient information, and by 
encouraging patients to report subjective experiences of adverse effects. EP adverse 
effects are among the most important reasons for non-compliance, causing subjective 
suffering, lowering of function level and social stigma (Lindström 1994, Owens 
1996). Despite the increasing amount of atypical antipsychotics available, EP 
symptoms still threaten the treatment of psychosis because: 1. Even atypical 
neuroleptics may cause EP symptoms (Miller et al. 1998, Barnes and McPhillips 
1999, Tarsy et al. 2002), especially akathisia, which is associated with a worse 
clinical outcome (Cohen et al. 1991) and 2. The clinicians’ ability to identify these 
adverse effects is generally poor, varying between 10% and 59% (Weiden et al. 1987, 
Hansen et al. 1992). 
 
The diagnostic criteria for acute NIA are described in DSM-IV (Table 2). DIA is 
classified into acute, chronic, tardive and withdrawal akathisia (Sachdev 1995a, 
1995b). Special subtypes of DIA described in the literature, such as subjective 
akathisia (Van Putten and Marder 1986) and hypokinetic akathisia (Tuisku et al. 
2000), are difficult to diagnose and sometimes impossible to assess by the most 
established rating scale, the Barnes Akathisia Rating Scale (BARS), which disregards 
the richness of clinical features (Cunningham Owens 1999). Differential diagnosis of 
DIA includes other types of akathisia like idiopathic akathisia, akathisia related to 
Parkinson’s disease, secondary akathisia related to head injury and pseudoakathisia, 
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suggested to be a variant of tardive dyskinesia rather than a form of akathisia (Stahl 
1985).  
 
NIA differs from TD by a prominent inner sense of discomfort, the voluntary nature 
of movements, earlier onset in the course of neuroleptic treatment and non-
involvement of the perioral area in contrast to TD (Munetz and Cornes 1983). A 
tardive form of NIA has also been described in which movements may be more 
stereotyped than in acute NIA (Sachdev 1994). Tardive akathisia (TA) is associated 
with neuropsychological deficits and negative symptoms in schizophrenia patients 
even more strongly than TD (Sachdev et al. 1996). TD often co-occurs with TA 
(Sachdev 1994) or chronic NIA (Barnes and Braude 1985), but the relationship 
between TD and TA is unclear (Sachdev et al. 1996). Although a causality or a 
successive continuum of symptoms has been suggested to exist between them, no 
evidence exists of interrelatedness between these disorders (Kahn et al. 1992). TD is 
differentiated from TA by less subjective awareness and control over motor 
symptoms, which are more purposeful in the latter (Sachdev 1994, American 
Psychiatric Association 2000). 
 
The most characteristic diagnostic sign for both acute and chronic akathisia is the 
subjective experience of an inability to keep the legs still. It is more specific to NIA 
than an overall sense of inner restlessness, which is also quite common in psychiatric 
patients without NIA and seems to diminish or disappear in chronic NIA (Barnes and 
Braude 1985). Differential diagnosis of akathisia is often difficult, and several other 
hyperkinetic states and disorders with psychomotor agitation have to be considered 
including psychotic agitation related to schizophrenia, agitation related to mood 
disorders, generalized anxiety, substance intoxication and -withdrawal syndromes, 
ADHD and RLS (American Psychiatric Association 2000). 
 
3.2. RLS 
 
Ekbom (1944) described an idiopathic syndrome, “Asthenia crurum paraesthetica”, 
referring to previous descriptions of “anxietas tibiarum”, which he later renamed 
“Restless legs syndrome” (1945, 1960). He described unpleasant lower limb 
paresthesias, “creeping or crawling” sensations elicited by sitting or lying down, 
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which cause an urge to move the legs or an inability to keep them still. The symptoms 
are mostly present in the evening and night-time and are relieved by moving the legs. 
Emotions do not seem to play a large role in RLS according to Ekbom’s original 
descriptions. 
 
RLS is a common, sometimes disabling and often misdiagnosed condition (IRLSSG 
1995), with both subjective sensations and objective motor symptoms (Montplaisir et 
al. 2000). The distressing subjective sensations may be present and incapacitating 
during the daytime, but the symptoms typically worsen at night, often leading to 
insomnia (Ekbom 1960, Montplaisir et al. 2000, Bassetti et al. 2001). Another 
harmful consequence of RLS is secondary depression (Trenkwalder et al. 1999b, 
Ulfberg et al. 2001a), which may affect one-third of these patients during their 
lifetime (Bassetti et al. 2001). Based on comorbidity findings, Pichietti et al. (1999) 
suggest that RLS may indirectly, through sleep disruption, lead to attention deficit 
hyperactivity disorder. RLS is considered to be both a sleep disorder and a movement 
disorder (Hening et al. 1999a, Amar 2001). 
 
The International Restless Legs Syndrome Study Group (IRLSSG 1995) has defined 
the diagnostic criteria for RLS (Table 2). Two of the essential diagnostic criteria of 
RLS, namely, “occurring with rest” and “during the night”, can be speculated to have 
a causal relationship, but actually they seem to be independent phenomena based on 
diurnal rest-activity and other symptom severity measurements (Hening et al. 1999b, 
Trenkwalder et al. 1999a). The differential diagnostic disorders to be considered are 
NIA (see section 3.5.1.), isolated periodic limb movement disorder without RLS, 
painful legs and moving toes syndrome, nocturnal leg cramps, restless insomnia, 
neuropathic pain syndromes, arthritis, anxiety syndromes, ADHD and other 
hyperactivity states such as hyperthyroidism and Tourette’s disorder  (Montplaisir et 
al. 2000, Allen and Earley 2001, Tan and Ondo 2001). 
 
The motor and sensory symptoms of RLS are typically localized to the lower limbs, 
but the upper limbs may also be involved (Bassetti et al. 2001). The motor 
hyperactivity of RLS patients during immobilization seems to consist of both short-
lasting, involuntary periodic leg movements (PLM) and more prolonged voluntary 
movements made by the patient to get rid of discomfort (Montplaisir et al. 1998). 
 35 
EMG recording during an immobilization test has been developed to measure 
symptom severity (Montplaisir et al. 1998). As most of the RLS patients exhibit PLM 
in EMG, the PLM index is often used to support a diagnosis of RLS (Montplaisir et 
al. 1998) and to monitor the severity of symptoms (Montplaisir et al. 1999). The 
periodic limb movement disorder (PLMD), however, is a distinct disorder, not always 
present in RLS (Allen and Earley 2001), including severe cases (Montplaisir et al. 
1997). Furthermore, it is a non-sensitive marker of RLS (Montplaisir et al. 1998). 
 
The prevalence of idiopathic RLS is estimated to be around 5% in the general 
population and to be age-related (Chokroverty and Jankovic 1999). According to an 
epidemiological questionnaire, frequent restless legs symptoms are reported by 3% of 
people aged 18-29 years, by 10% of those aged 30-79 years and by 19% of those aged 
over 79 years. Somatic reasons for symptoms were not excluded in this study (Phillips 
et al. 2000). Family history is estimated to be present in one-third to two-thirds of 
RLS patients and an autosomal dominant model of inheritance has been suspected 
(Chokroverty and Jankovic 1999, Lazzarini et al. 1999). A positive family history is 
more frequent in idiopathic RLS than in secondary RLS (Winkelmann et al. 2000). 
The hereditary form of RLS presents with clinical symptoms similar to the non-
hereditary form but has an earlier onset (Winkelmann et al. 2000). Recent findings 
concerning genetic penetrance suggest a heterogenic genetic aetiology (Lazzarini et 
al. 1999), and some evidence for a recessive mode of inheritance has been found in a 
linkage study of one family (Desaultes et al. 2001).  
 
Secondary RLS may be related to Parkinson’s disease, neuropathy, uremia, iron 
deficiency, pregnancy and rheumatoid arthritis (Goodman et al. 1988, Salih et al. 
1994, Chokroverty and Jankovic 1999, Stocchi et al. 2000, Allen and Earley 2001). 
Primary, idiopathic RLS (sporadic or genetic) may be difficult to differentiate from 
secondary RLS (Chokroverty and Jankovic 1999), and the categorization between 
primary and secondary forms of RLS may sometimes be unclear since axonal 
neuropathy (Iannaccone et al. 1995) and abnormally low serum iron levels (Aul et al. 
1998) seem to be common subclinical findings in primary RLS. After findings of 
slight peripheral axonal neuropathy in each patient of a study sample, the previous 
diagnosis of “primary” RLS for these patients may be questioned (Iannaccone et al. 
1995). Low serum ferritine level, an indicator of iron deficiency is correlated with 
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subjective RLS symptom severity and decreased sleep efficiency but not with number 
of PLMS (Sun et al. 1998).  
 
A defect in iron metabolism has been suggested to be involved in the pathophysiology 
of RLS, as iron is a component of the D2 and µ-opiate receptors (Aul et al. 1998), 
which seem to have central roles in the pathophysiological mechanisms according to 
pharmacological studies (Chokroverty and Jankovic 1999). There is evidence of 
treatment response both to dopaminergic drugs (von Scheele 1986, Kaplan et al. 1993, 
Earley et al. 1998) and to opioids (Hening et al. 1986, Lauerma and Markkula 1999), 
but the response to opioids can be inhibited by antidopaminergics (Montplaisir et al. 
1991), which further supports the dopaminergic model as the primary 
pathophysiological mechanism in RLS (Earley et al. 2001).  
 
A PET study (Turjanski et al. 1999) reveals reduced striatal dopaminergic function in 
symptomatic RLS patients. Another PET study shows the same finding in RLS 
patients with PLM disorder (Ruottinen et al. 2000). The dopaminergic abnormalities 
in the basal ganglia of RLS patients seem to be functional, rather than 
neurodegenerative, because they were not found in the basal ganglia of RLS patients 
in an asymptomatic phase (Trenkwalder et al. 1999c). The intracortical inhibition 
measured by transcranial magnetic stimulation (TMS) is apparently reduced in RLS. 
The TMS findings suggest that the functional pathology is a subcortical rather than a 
primary cortical or corticomuscular phenomenon (Tergau et al. 1999).   
 
To date, dopaminergic drugs are the best studied and most effective agents for 
treatment of RLS (Chesson et al. 1999). The largest number of studies have been 
conducted on levodopa compounded with carbidopa or benserazide, but rebound 
restlessness is often a clinical problem in these treatments (Hening et al. 1999a, 
Montplaisir et al. 1999). In any case, treatment with dopamine agonists may be more 
effective (Hening et al. 1999a). Among dopamine agonists, bromocriptine and 
pergolide are associated with adverse effects that limit their clinical usefulness, but 
pramipexole has proved to be both safe and a potent therapeutic agent for RLS 
(Montplaisir et al. 1999). 
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3.3. ADHD in antisocial personality disorder (ASP) 
 
ADHD is the most common psychiatric disorder of childhood, affecting 
approximately 5% of school-aged children (Szatmari 1992), but in adolescents and 
adults the prevalence is much lower (Cuffe et al. 2001). The combined type of ADHD 
fulfills both the criteria for attention deficit as well as for hyperactivity and 
impulsiveness, whereas the subtypes (predominantly inattentive and predominantly 
hyperactive type) do not fulfill the criteria for both symptom dimensions (American 
Psychiatric Association 2000) (Table 2). Prospective longitudinal studies show that 
part of the childhood onset ADHD symptoms persists in nearly half of the subjects 
until adolescence or early adulthood and that ADHD is a risk factor for conduct 
disorder, ASP and substance abuse (Gittelman et al. 1985, Mannuzza et al. 1993). 
ADHD and conduct disorder share a common genetic aetiology, and ADHD with a 
comorbid conduct disorder seems to be a more severe variant of ADHD (Thapar et al. 
2001) and to have a worse prognosis (Taylor 1999) than ADHD alone. Taylor (1999) 
integrates his own findings and evidence from other studies with a psychological 
approach in concluding that ADHD is a biological and psychosocial risk factor for 
conduct disorder, which is likely to develop in ADHD children of dysfunctional 
families. Conduct disorder, by contrast, does not predispose to ADHD. 
 
A history of ADHD is commonly found in subjects with ASP, and ADHD is 
considered to be one of the precursors of ASP in the presence of conduct disorder 
(McCracken et al. 2000). The diagnostic criteria of ASP include more or less learned 
social features and some seemingly more biological aspects of behaviour, such as 
aggressiveness and impulsiveness, the latter of which is also a diagnostic feature of 
ADHD (American Psychiatric Association 2000). Shared neurobiological features 
appear to be present in ASP and ADHD (Renfrew 1997). A reduction in aggression 
with psychostimulants may result from enhanced attention and intellectual functions 
or from a reduction in impulsiveness (Renfrew 1997, Cherek and Lane 2000). The 
response of aggressiveness to psychostimulants supports the role of D in regulation of 
aggressiveness among other transmitters including NA, 5-HT and ACh (Renfrew 
1997). 
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The central pathophysiological theory of hypodopaminergic aetiology in ADHD 
arises from the therapeutic effect of psychostimulants (Seeman and Madras 1998) and 
is supported by dopamine-related candidate gene findings (Thapar et al. 1999). The 
mode of inheritance seems to be polygenic in ADHD, and interactions between 
serotonergic and dopaminergic neurotransmitter systems are involved in the 
pathophysiology (Quist and Kennedy 2001). The central role of dopaminergic circuits 
in the pathophysiology of ADHD is further supported by findings of striatal 
hypoperfusion in ADHD (Lou et al. 1989). A developmental defect in frontostriatal 
circuits has been suggested to be one of the pathophysiological mechanisms (Toft 
1999). The frontostriatal dopaminergic deficit has gained growing evidence as a 
central pathophysiological mechanism of ADHD affecting inhibition and working 
memory (Lewy and Swanson 2001). 
 
The recommended primary pharmacological treatment options based on research 
evidence in ADHD are the psychostimulants methylphenidate and 
dextroamphetamine. The use of pemoline is limited because of reported liver toxicity. 
Other, secondary options include antidepressants and clonidine, which reduces the 
autonomic sympathicotonia by activating central alpha-2 adrenergic receptors.  
Clonidine can be used to treat comorbid aggressive symptoms and tics in ADHD. 
(Pliszka et al. 2000).   
 
3.4. Asperger’s disorder 
 
Asperger’s disorder is a disorder in the autism spectrum. The syndrome now called 
Asperger’s disorder is retrospectively assumed to have been first described using the 
label “schizoid personality disorder” (Gillberg 1998a), showing a possible diagnostic 
overlap between schizophrenia spectrum and autism spectrum disorders, especially 
concerning Asperger’s disorder or high-functioning autism and childhood-onset 
schizophrenia (Gillberg 1998b). More long-term follow-up studies are needed before 
high-functioning autism and Asperger’s disorder can be concluded to be different 
disorders (Gillberg 1998a). This new diagnostic concept of Asperger’s disorder, still 
under some debate (Volkmar et al. 2000), indicates a syndrome characterized by 
altered social interactions, restricted interests and repetitive, stereotyped behaviour, as 
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in autism, but different from the latter in that it does not display any significant delay 
in acquisition of language, psychomotor and cognitive skills (Table 2).  
 
The prevalence of autism spectrum disorders, including childhood autism, Asperger's 
syndrome, disintegrative disorder and atypical autism, is estimated to be at least 4-5 
per 1000 children. Asperger's syndrome occurs at a minimum rate of 26-36 in 10 000 
children (Gillberg and Wing 1999). Autism spectrum disorders are probably caused 
by the interaction of several mutant genes, which are likely to be located on different 
chromosomes (Gillberg 1998c). 
 
Because of the scarcity of reports on neuroanatomical and neurochemical findings in 
Asperger’s disorder, it is necessary to rely on studies of autistic patients in order to 
elaborate physiopathological hypotheses (Godbout et al. 2000). Computed 
tomography demonstrates a reduced density of the caudate nucleus (Jacobson et al. 
1988), and PET reveals presynaptic, prefrontal hypodopaminergia in autism (Ernst et 
al. 1997). Obvious hypofunction in the midbrain dopaminergic neurons of autistic 
children may lead to secondary dopaminergic hypersensitivity (Segawa and Nomura 
1992). Primary dopaminergic dysfunction and structural abnormalities in the basal 
ganglia may explain the vulnerability to neuroleptic-induced EP symptoms in autistic 
patients (Campbell et al. 1997).  
 
Movement disorders are common in Asperger’s disorder, manifesting clinically as 
clumsiness (Gillberg 1995, Smith 2000, Weimer et al. 2001), lack of motor co-
ordination (Miyahara et al. 1997) and stereotypic, repetitive movements (Ringman 
and Jankovic 2000). The clumsiness and motor inco-ordination observed in 
Asperger’s disorder patients are probably related to a proprioceptive deficit (Weimer 
et al. 2001). In addition to these typical motor disorders, patients may suffer from 
other motor disorders associated with comorbid disorders such as Tourette’s disorder 
(Kadesjö and Gillberg 2000) and ADHD (Ghaziuddin et al. 1998). Moreover, 
attention deficit symptoms not fulfilling the diagnostic criteria of ADHD are very 
common in disorders in the autism spectrum. Both motor hyperactivity and 
hypoactivity are encountered in autism (Gillberg and Billstedt 2000). Other 
psychiatric disorders showing comorbidity with Asperger’s disorder are affective, 
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anxiety and obsessional disorders, psychoses and antisocial behaviour (Green et al. 
2000). 
 
The existence of true comorbidity between Asperger’s disorder, Tourette’s 
disorder and OCD may be questioned because of the overlapping features of 
these disorders (Gillberg 1998a). The comorbidity with externalizing disorders 
may be partially explained by the primary difficulties in social perception, 
leading to irritability and impulsivity, but according to clinical research data, a 
simple association between the level of social impairment in Asperger’s 
disorder and the degree of psychiatric comorbidity has not been found (Green et 
al. 2000). The comorbidity and overlapping features between these disorders 
may be due to a common developmental defect in frontostriatal circuits 
(Gillberg 1998a), predisposing to a broad spectrum of neuropsychiatric 
symptoms modulated individually by genes and environmental factors.    
 
The pharmacological treatment of Asperger’s disorder may be focused on 
autistic symptoms or on current disturbing secondary symptoms, such as 
aggressive behaviour and hyperactivity, but use of pharmacological 
interventions is limited by adverse effects (Nyden et al. 2000). Because 
pharmacotherapy is unlikely to alter most core features of autism, including 
impairments in communication, social interaction, stereotyped behaviour and a 
narrow focus of preoccupation, the more usual targets for treatment are the 
secondary symptoms or comorbid disorders (Arnold et al. 2000). 
Antidopaminergic, antiserotonergic, serotonine re-uptake inhibiting, opiate 
antagonist and dopamine agonist drugs have been explored in treatment of 
autistic disorders, among which haloperidol has been studied most 
systematically. Most of these drugs reduce hyperactivity symptoms and 
haloperidol seems to be effective in treating disruptive symptoms (Campbell 
and Cueva 1995). Antipsychotics have been used cautiously in autistic disorders 
because of EP adverse effects (Scahill and Koenig 1999). The high rate of 
baseline motor abnormalities implicates careful screening and monitoring of 
movement disorders during treatment (Campbell et al 1997). The serotonin re-
uptake inhibiting effect may be effictive in treating core symptoms of autism, 
while noradrenaline re-uptake inhibition is useful in treating comorbid ADHD 
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symptoms (Hollander et al. 2000). Valproate may be beneficial in treating 
affective instability, impulsiveness and aggressive behaviour (Hollander et al. 
2001). 
 
3.5. Common features  
 
3.5.1. Clinical and diagnostic 
 
In the literature, the descriptions of RLS are often intermixed with those of akathisia 
(Adler et al. 1989, Sachdev 1995a). Blom and Ekbom (1961) noted a clinical 
similarity between RLS, earlier described by Ekbom (1944, 1960), and NIA, but they 
also remarked that NIA symptoms, unlike restless legs symptoms, were present 
during the daytime and did not disturb sleep. Furthermore, they described paresthesias 
and restlessness to be confined to the legs in RLS, whereas in NIA the restlessness 
may be more generalized. 
 
The question has arisen whether NIA is a form of RLS (IRLSSG 1995) as they 
share some diagnostic (Table 2), clinical and polysomnographic features  
(Walters et al.1991, Allen and Earley 2001). Several differences have, however, 
been described: more localization of symptoms in the lower limbs and more 
pronounced dysesthesia in RLS, worsening or triggering of the symptoms in a 
lying position in RLS, different circadian distribution of the symptoms, more 
disturbed sleep pattern and more PLMS in RLS (Walters et al. 1991, Sachdev 
1994, Chokroverty and Jankovic 1999, Montplaisir et al. 2000, Allen and Earley 
2001). Furthermore, the urge to move in akathisia is more often generated by an 
inner sense of restlessness than by specific lower limb sensations typical of RLS 
(Walters et al. 1991, IRLSSG 1995). Akathisia related to Parkinson’s disease or 
other organic brain diseases has not been fully characterized (Sachdev 1995a), 
but NIA is defined by diagnostic criteria in DSM-IV (American Psychiatric 
Association 2000) and is distinguishable from RLS by its aetiology 
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Table 2: DIAGNOSTIC CRITERIA OF SELECTED NEUROPSYCHIATRIC DISORDERS  
 
I. Neuroleptic-induced acute akathisia (NIA) 
 
A. Development of subjective complaints of restlessness after exposure to a neuroleptic 
medication. 
B. At least one of the following observed: (1) fidgeting movements or swinging of the legs, 
(2) rocking from foot to foot while standing, (3) pacing to relieve restlessness, (4) inability to 
sit still for at least several minutes. 
C. Onset of symptoms in A and B occurs within 4 weeks of initiating or increasing the dose of 
the neuroleptic, or of reducing medication used to treat acute extrapyramidal symptoms. 
D. Symptoms in A are not better accounted for by a mental disorder. 
E. Symptoms in A are not due to a non-neuroleptic substance or to a neurological or other 
general medical condition. 
(DSM-IV, American Psychiatric Association 2000) 
 
II. Restless legs syndrome (RLS) 
 
Essential features: 
 
A. Desire to move the limbs usually associated with paresthesias or dysesthesias. 
B. Motor restlessness. 
C. Symptoms are worse or exclusively present at rest with at least partial or temporary relief 
with activity. 
D. Symptoms are worse during the evening or at night. 
 (IRLSSG, 1995) 
 
III. Attention deficit hyperactivity disorder (ADHD) 
 
A. Either six or more symptoms of inattention, or six or more symptoms of hyperactivity-
impulsivity (e.g. fidgeting with hands or feet or squirming in seat, leaving situations in which 
remaining seated is expected,  running or climbing in inappropriate situations). 
B. Some symptoms that caused impairment were present before the age of 7 years. 
C. Some impairment from the symptoms is present in two or more settings. 
D. Clear evidence of clinically significant impairment in social, academic or occupational 
functioning. 
E. Symptoms do not occur exclusively during the course of a pervasive developmental 
disorder, schizophrenia or another psychotic disorder and are not better accounted for by 
another mental disorder. 
 (DSM-IV, American Psychiatric Association 2000) 
 
IV. Asperger’s disorder 
 
A. Qualitative impairment in social interaction 
B. Restricted repetitive and stereotyped patterns of behaviour, interests and activities (e.g. 
stereotyped and repetitive motor mannerisms). 
C. The disturbance causes clinically significant impairment in social, occupational or other 
important areas of functioning.   
D. No clinically significant delay in language. 
E. No clinically significant delay in cognitive development, age-appropriate self-help skills, 
adaptive behaviour or curiousity about the environment. 
F. Criteria are not met for another specific pervasive developmental disorder or 
schizophrenia. 
(DSM-IV, American Psychiatric Association 2000)   
 
 
 
.  
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Antidepressants have been suggested to be an aetiological factor for both akathisia 
(Zubenko et al. 1987) and RLS (Markkula and Lauerma 1997), which complicates the 
differential diagnosis. Actually, the clinical picture of akathisia cases described by 
Zubenko et al. (1987) also comprises features typical of RLS, such as worsening of 
symptoms when going to sleep and difficulties in falling asleep because of 
uncomfortable leg sensations. 
 
Motor restlessness is an essential diagnostic feature of NIA, RLS and ADHD 
(Table 2). In ADHD, two items in the diagnostic criteria are similar to NIA 
symptoms: fidgeting with feet while seated and inability to remain seated (Table 
2). Both akathisia and ADHD are related to aggressive behaviour (Ratey and 
Gordon 1993). There is comorbidity and overlapping features between 
Asperger’s disorder and ADHD (Ghaziuddin et al. 1998, Gillberg 1998a) and  
the under-diagnosis of these developmental disorders in childhood may lead to 
externalizing  behaviour problems and impaired adaptation to society (Nyden et 
al. 2000). Motor restlessness may also manifest in autistic disorders, among 
other motor abnormalities (Gillberg and Bilstedt 2000), such as repetitive motor 
mannerisms typical of Asperger’s disorder (Table 2). 
 
3.5.2. Pathophysiological 
 
PET findings of striatal dopaminergic hypofunction have been made in the caudatum 
and putamen areas in NIA (Farde et al. 1992) and RLS (Turjanski et al. 1999, 
Ruottinen et al. 2000), and are iatrogenic in NIA. Striatal dopaminergic deficit in 
ADHD has gained evidence from dopamine transporter findings in brain imaging and 
genetic studies (Thapar et al. 1999, Krause et al. 2000). Prefrontal hypodopaminergia 
has been demonstrated in autism by PET (Ernst et al. 1997), and increasing evidence 
exists of frontostriatal dysfunction in both autistim and ADHD (Gillberg 1998a). 
 
Attempts have been made to explain the familial comorbidity between RLS and 
ADHD by hypodopaminergic pathophysiology, a common genetic basis for these 
disorders or a causality related to RLS-induced sleep disruption (Picchietti et al. 
1999).  
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3.5.3. Pharmacological 
 
The beta-adrenergic blocking agent, propranolol, an effective treatment option in NIA 
(Adler et al. 1989, Poyurovsky and Weizman 2001), is also reported to reduce 
aggressive symptoms related to ADHD (Mattes 1990). 
 
Clonidine, which has anti-adrenergic and anti-aggressive properties, is a secondary 
treatment option for both NIA (Adler et al. 1987, Miller and Fleischhacker 2000, 
Taylor et al. 2001) and ADHD (Pliszka et al. 2000). The hyperactivity and irritability 
symptoms in autism are also reported to respond to clonidine (Fankhauser et al. 1992, 
Jaselskis et al. 1992).  
 
Surprisingly, some of the core autistic symptoms can be relieved by psychostimulant 
treatment focused on comorbid ADHD in autism (Handen et al. 2000). The 
psychostimulant treatment increases the striatal dopaminergic transmission by 
blocking the D transporter or by releasing D into the synaptic cleft (Seeman and 
Madras 1998, Krause et al. 2000). 
 
3.6. Accelerometric studies on selected disorders 
 
Accelerometric methods (see section 2.4.) measure locomotor activity by ambulatory 
activity monitors. In activity monitors, there are three principal modes of data 
collection known as “time above threshold”, “zero-crossing” and “digital integration”. 
In the first one, the monitor tracks the length of time that elapses from the point when 
acceleration exceeds a threshold value until it falls below the threshold. In the second 
mode, the monitor detects the number of times that acceleration crosses the zero point 
within a certain time period. In digital integration, the amount of acceleration is 
recorded and sampled at a high rate, and these values are used to calculate the average 
activity level within a time window (Gorny and Allen 1999). All the accelerometric 
monitors measure locomotor activity quantitatively, and some of them also allow 
qualitative motion analysis. The smaller the time window, the higher the time 
resolution of the movement. 
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Altered locomotor activity is an important sign of several psychiatric disorders 
(Teicher 1995), whereas specific motor disturbances in psychiatric disorders are 
obvious clinical signs of organic aetiology in the brain (Beier 1997). An increasing 
amount of data on accelerometric studies in psychiatry has been collected, and 
activity monitoring has been suggested to be a valuable research tool of potential aid 
to clinicians in diagnosis and prediction of treatment response (Teicher 1995). The 
customary use of accelerometric activity monitoring is diurnal recording with a 
relatively long time window ranging between several minutes and one hour. In diurnal 
activity monitoring, the monitors have typically been attached to the non-dominant 
wrist. However, such movement disorders as NIA and RLS are better manifested in 
the lower limbs than anywhere else. Gardos et al. (1992) and Mills et al. (1993) have 
created new methods of quantifying lower limb activity in these disorders.  
 
3.6.1. NIA 
 
Gardos et al. (1992) measured diurnal motor activity in NIA from the non-dominant 
ankle, comparing patients of different diagnostic categories with or without NIA and a 
group of healthy controls. The activity appeared to be influenced by both NIA and the 
psychiatric diagnosis. The diurnal activity seemed to be more related to psychiatric 
diagnosis than NIA, because manic patients and healthy controls were the most active 
in diurnal measuring. However, within the group of schizophrenics, NIA had an 
increasing effect on daytime motor activity. The positive correlation  between NIA 
severity rating and daytime activity level was statistically significant. Poyurovsky et 
al. (2000) recorded the diurnal activity of schizophrenic patients from the non-
dominant wrist, comparing patients with NIA and those without; he observed a higher 
level of diurnal motor activity in NIA patients. No difference in quantitative activity 
during sleeping hours was found between the groups. 
 
In addition to quantitative studies, qualitative motion analysis has been performed in 
NIA. Accelerometric findings of a rhythmic, 0.5-3 Hz lower limb movement pattern 
in NIA (Braude et al. 1984, Rapoport et al. 1994) are consistent with the results of 
EMG studies (Cunningham et al. 1996). Abnormal, periodic movement patterns of a 
constant waveform, frequency and amplitude are reproducible accelerometric findings 
in NIA (Rapoport et al. 1994). 
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3.6.2. RLS 
 
In RLS, motor activity is more often recorded by EMG than by accelerometric 
methods. In sleep studies, the role of ambulatory activity monitoring has traditionally 
been in differentiation between sleep and wakefulness. Sadeh et al. (1989) validated 
wrist actometry for this purpose. Mills et al. (1993) examined the usefulness of 
actometry for objectively assessing motor RLS symptoms with bilateral leg activity 
monitors to find a time-saving and cost-effective alternative to polysomnography. The 
quantitative assessment of lower limb activity showed the treatment response in 
parallel with other symptom severity measures. Later, actometry was validated by 
Kazenwadel et al. (1995) and utilized in sleep studies (Trenkwalder et al. 1995, 
Collado-Seidel et al. 1999) as a method comparable to EMG in assessment of PLM. 
Actometry has also been used to measure quantitative motor activity as a marker of 
symptom severity in examining the circadian rhythm of RLS (Hening et al. 1999b). 
 
3.6.3. ADHD 
 
Increased diurnal activity in ADHD has been quantified by waist-worn activity 
monitors. The increase of diurnal activity differentiated hyperactive boys from 
controls as well as a standardized measure of attention (Porrino et al. 1983a). Diurnal 
actometric recording from the non-dominant wrist revealed an equal hyperactivity in 
predominantly inattentive and combined ADHD subtypes (Dane et al. 2000). 
Hyperactivity in actometry is a more discriminative feature of ADHD than inattention 
and dyscontrol in psychometric test battery (Halperin et al. 1992). In actometric 
studies, hyperactivity seems to be related to situations demanding self-regulation 
(Dane et al. 2000), and motor activity measured during a cognitive task, for example, 
is a good measure of symptom severity (Reichenbach et al. 1992). In fact, the diurnal 
hyperactivity of children with ADHD appears to be due more to the relative absence 
of quiescent periods than to the presence of extremely active periods. This is 
consistent with the actometric finding that the increase of activity in ADHD children 
compared with controls is most prominent during academic school activities while 
sitting in the classroom (Porrino et al. 1983a), and with the clinical observation of 
difficulties in sitting still (Teicher 1995).  
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3.6.4. ASP 
 
Diurnal activity has been studied in violent ASP patients by actometric recording 
from the non-dominant wrist. The patients demonstrated an overall increase of diurnal 
activity, which was expected to be related to the common history of ADHD in these 
patients. In a subgroup of antisocial violent offenders with intermittent explosive 
disorder, the day and night activity levels were indistinguishable,  indicating a 
desynchronized diurnal rhythm (Virkkunen et al. 1994).   
 
3.6.5. Asperger’s disorder 
 
In Asperger’s disorder, no studies are yet available using accelerometric methods 
despite the prominent motor symptoms and abnormal levels of motor activity in this 
disorder. However, the sleep patterns of autistic children have been studied by diurnal 
actometric recording with a wrist monitor (Hering et al. 1999). 
 
4. RATIONALE, HYPOTHESES AND PURPOSES OF EACH STUDY        
 
Motor restlessness, which can be a manifestation of many underlying disorders, is 
often poorly recognized and underdiagnosed in clinical practice and probably too 
often simply attributed to anxiety. Early diagnosis allows proper treatment of 
hyperactivity states, and thus, careful evaluation and differential diagnostics are 
required. The two major conditions to consider in patients who present with motor 
restlessness are NIA and RLS. In addition, ADHD and other neuropsychiatric 
disorders should be taken into account (Tan and Ondo 2001).  
 
These studies aimed to offer a window to understanding the role of motor abnormality 
in neuropsychiatric disorders and to bring an objective and simple method for motor 
assessment into clinical neuropsychiatry. Accelerometric-based actometry offers an 
objective and naturalistic method for both quantitative and qualitative studies of rest-
activity. Actometry has been hailed by Teicher (1995) as an important research tool in 
clinical psychiatry. It is non-invasive and does not disturb the normal moving of the 
subject. 
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The hypothesis of these studies was that measuring motor activity during rest (sitting) 
by three-channel actometry in a standardized setting would yield abnormal 
quantitative and qualitative results and would enable characteristic motor features of 
NIA, RLS, ADHD in ASP and Asperger’s disorder to be uncovered.  
 
General purposes of these four studies were to develop a standardized actometric 
method for diagnostics and monitoring of motor symptoms in neuropsychiatric 
disorders and to identify characteristic motor signs in NIA, RLS, ADHD and 
Asperger’s disorder. 
 
4.1. NIA study 
 
The assessment and monitoring of NIA rely on rating scales, which are typically 
based on the clinicians’ subjective judgements (Jankovic and Frost 1981, 
Cunningham Owens 1999). A need exists to develop new, objective methods for 
diagnostics and to reliably assess symptom severity in this harmful and 
underdiagnosed adverse effect of antipsychotic drugs. This need for objective 
methods for identification of NIA has prompted attempts to establish physiological 
correlates for NIA (Poyurovsky et al. 2000). When publishing the currently most 
established rating scale for NIA, Barnes (1989) discussed testing its validity by using 
an electronic movement meter to objectively quantify the restless activity of patients. 
 
Previous accelerometric findings (Gardos et al. 1992, Poyurovsky et al. 2000) of 
diurnal activity in NIA are difficult to interpret because not all the motor activity can 
be accounted for akathisia and even hospitalized patients can have very different daily 
routines and activities. Quantification of motor activity and qualitative analysis of 
movement patterns should occur in a standardized setting, which is still as naturalistic 
as possible to allow spontaneous, individual motor activity of subjects to take place.  
 
As the term “akathisia” suggests, the inability to sit still is a pathognomonic and 
diagnostic feature of NIA (American Psychiatric Association 1994, 2000), leading to 
the hypothesis that rest-activity during sitting would be abnormal, both quantitatively 
and qualitatively, in NIA.  
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The specific purpose of this study was to develop actometric diagnostics and 
monitoring of akathisia and to find an objective diagnostic marker and indicator of 
symptom severity in NIA. 
 
4.2. RLS study 
 
The severity of symptoms in RLS has also been difficult to quantify. Due to the lack 
of physiological markers, non-validated rating scales have been used to measure 
symptom severity (Chokroverty and Jankovic 1999). Both subjective and objective 
assessment methods, including actometry, should be further developed to provide 
more reliable evidence of therapeutic impact (Hening et al. 1999a). The most 
commonly used objective diagnostic sign and measure of symptom severity, the PLM 
index, is unspecific and non-sensitive for RLS (Montplaisir et al. 1997, 1998, 1999). 
Moreover, it is not strictly a quantitative measure, as it requires the visual 
identification of typical movement patterns. EMG recording of quantitative motor 
activity in a standardized setting requiring immobilization of the subject (Montplaisir 
et al. 1998) has the disadvantage of a non-naturalistic laboratory method, not allowing 
natural, spontaneous movement of subjects.  
 
As the diagnostic criteria of RLS (IRLSSG 1995) include a desire to move, 
uncomfortable sensations and motor restlessness, but not necessarily PLM, voluntary 
motor restlessness in response to subjective symptoms is an essential feature of RLS. 
Because the symptoms are elicited or worsened by rest, natural motor activity during 
rest is hypothesized to be a central marker of symptom severity.  
 
The purpose was to develop actometric diagnostics and monitoring of RLS by finding 
an objective diagnostic marker and indicator of symptom severity in RLS. Another 
purpose was to clarify differential diagnostics of motor symptoms between RLS and 
NIA.  
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4.3. ASP/ADHD study 
 
As hyperactivity is the most discriminative feature of ADHD (Halperin et al. 1992) 
and is most prominent in structured situations requiring inhibited activity (Teicher 
1995, Dane et al. 2000), a quantitative assessment of hyperactivity in a standardized 
setting is expected to be a useful measure of symptom severity. Since some of the 
ADHD symptoms may persist until adulthood (Gittelman et al. 1985, Mannuzza et al. 
1993) and are linked to antisocial development (McCracken et al. 2000), the objective 
evaluation of motor hyperactivity in an adult sample of ASP patients with ADHD is 
of interest. Hyperactivity may be more persistent than other symptoms of ADHD in 
adulthood (Teicher et al. 1995).  
 
The quantification of rest-activity and qualitative analysis of movement patterns 
during rest in ASP with ADHD was hypothesized to yield abnormal findings and to 
offer a possibility of comparison with NIA, which may serve as a model of 
hypodopaminergic hyperactivity disorder. The central hypodopaminergic 
pathophysiological model of ADHD elicits the hypothesis of similarities between NIA 
and ADHD hyperactivity.  
 
The purpose was to assess residual hyperactivity symptoms in adult ADHD in a 
violent, antisocial population and to compare the actometric findings between ADHD 
and NIA. 
 
4.4. Asperger study 
 
Because movement disorders, motor hyperactivity and hypoactivity are reported in 
autism (Gillberg 1995, Gillberg and Billstedt 2000, Ringman and Jankovic 2000, 
Smith 2000, Weimer et al. 2001), an objective quantification of rest-activity and 
qualitative analysis of movement patterns with actometry would be useful for clinical 
and scientific neuropsychiatric assessment. The abnormal level of motor activity 
described in autism has never been objectively quantified before. The motor 
disturbance related to autism seems to be especially prominent in Asperger’s disorder 
(Iwanaga et al. 2000). 
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The overlapping features with schizophrenia spectrum disorders (Gillberg 1998b), 
motor features in common with Parkinson’s disease (Vilensky et al. 1981), 
vulnerability to neuroleptic-induced EP symptoms (Campbell et al. 1997) and 
hypodopaminergic findings in autism (Ernst et al. 1997) suggest the possibility of 
idiopathic EP movement disorders, such as akathisia in Asperger’s disorder, which 
were anticipated to show up in actometric recording of rest-activity. The rest-activity 
of Asperger patients was hypothesized to be abnormal. 
 
The purpose was to quantify motor activity at rest and to find possible abnormal 
movement patterns. 
 
5.  SUBJECTS 
 
5.1. Ethical considerations  
 
An informed consent was used in each of these studies, and they were all approved by 
the Ethics Committee of Helsinki University Central Hospital (HUCH). Ambulatory 
monitoring by actometry is a non-invasive method that does not cause any pain for the 
subjects. 
 
5.2. NIA study 
 
Ten NIA patients were recruited from hospitalized psychiatric patients at HUCH 
either referred to treatment for psychotic disorder or referred to the NIA study. The 
clinicians in charge of the treatment made the initial diagnosis of NIA and excluded 
psychotic agitation before allowing the patients to enter the study. Inclusion criteria 
were a diagnosis of acute NIA as defined by DSM-IV (American Psychiatric 
Association 1994), sufficient co-operativeness for the study procedures and an age 
between 18 and 65 years. Exclusion criteria were acute abstinence syndromes and 
recent substance abuse, clinically relevant somatic or neurological disorders, and 
clinically observable neuroleptic-induced parkinsonian symptoms to exclude the 
possible interfering effect of tremor or hypokinesia on motor activity. Laboratory 
abnormalities were exluded by a test battery including blood cell count, blood 
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glucose, serum transaminases, glutamyl-transferase, creatinine and thryroid-
stimulating hormone.  
 
An age- (+/- 5 years) and sex-matched healthy control was selected for each patient 
among hospital employees. Exclusion criteria for the healthy controls were the same 
as for the NIA patients, in addition to current use of any medication, and any self-
reported psychiatric disorders. The mean age of the NIA patients was 34.5 years and 
35.3 of the controls. Subjects comprised five female and five male patients with 
schizophrenia spectrum psychotic disorder. Seven patients were on conventional 
neuroleptics, two patients were taking risperidone together with a sedative, low-
potency neuroleptic, and one used sulpiride. All the NIA patients were able to 
maintain a sitting position for the recording time (30 min) despite an akathisia-related 
urge to move. 
 
5.3. RLS study 
 
Study subjects comprised 15 patients with idiopathic RLS, recruited by a monthly 
health magazine and a control group of 15 healthy hospital employees.  
 
Inclusion criteria for the RLS patients was an age of 18-65 years and a diagnosis of 
RLS (IRLSSG 1995) together with chronic (>1 year), frequent (>50% of nights) and 
subjectively distressing or harmful symptoms. Exclusion criteria were current 
medication or medication during the past two weeks, a history of regular or long-term 
use of hypnotics, sedatives, dopaminergic- or other psychoactive drugs, major somatic 
illnesses or traumas, secondary causes of RLS, any medical causes of insomnia other 
than RLS, any clinical sleep disorders other than RLS, and any past or present 
psychiatric axis 1 disorders uncovered during a structured clinical interview for 
diagnosis (SCID) (First et al. 1997a). Axis 2 disorders were also controlled for by 
SCID (First et al. 1997b), although they were not an exclusion criterion. Clinical 
somatic and standardized neurological examinations with laboratory tests (blood cell 
count, serum ferritin, serum glucose, serum creatinine and serum glutamyl-
transferase) were performed.  
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Healthy controls aged between 18 and 65 years were included. Exclusion criteria were 
the same as listed above, except that psychiatric exclusion was based on their own 
report instead of SCID, and the clinical somatic assessment included only the 
laboratory tests and taking of medical history if no reason for further examination 
emerged. Furthermore, any reported RLS symptoms were exclusion criteria for the 
control group.  
 
The mean age in the RLS group was 50.3 years (SD 11.2, range 26-62) and in the 
control group 49.3 years (SD 6.46, range 33-57), the difference between the groups 
being non-significant  (t=0.300, p=0.767). Male to female ratio was 1:14 in both 
groups. No significant differences were present in the haemoglobin (t=0.109, 
p=0.914) and serum ferritin levels (t=1.19, p=0.246) between the RLS (mean 
haemoglobin 138, SD 12.0, mean serum ferritin 60, SD 54.7) and the control (mean 
haemoglobin 138, SD 11.5, mean serum ferritin 41, SD 30.1) groups.  
 
5.4. ASP/ADHD study 
 
Fifteen ASP patients with ADHD and 10 NIA patients were recruited from the 
Department of Psychiatry of HUCH and the Hesperia Psychiatric Hospital. The 
control sample consisted of 15 employees or medical students of HUCH. 
 
The ASP/ADHD sample comprised consecutive cases of violent offenders in court-
ordered mental examination by the Forensic Psychiatric Department of HUCH. 
Subjects with a diagnosis of ASP according to diagnostic interview (First et al. 1997b) 
and aged between 18 and 65 were included. All of the subjects of this sample had a 
history of ADHD symptoms based on subjective reports, reports of other informants 
and childhood records. The symptoms retrospectively fulfilled the diagnostic criteria 
for ADHD in DSM-IV (American Psychiatric Association 2000). Most of them 
displayed persistent residual symptoms of childhood ADHD. Current restless 
psychiatric conditions (mania, agitated depression, generalized anxiety) were 
excluded by SCID (First et al. 1997a). Exclusion criteria were current medication, 
physical illness or substance abuse during the last two months. Abstinence was 
controlled by urine screening. A history of neurological disorder other than ADHD 
was also an exclusion criterion.  
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Laboratory abnormalities were excluded in both the ASP/ADHD group and NIA 
group by a test battery including blood cell count, blood glucose, serum 
transaminases, glutamyl-transferase, creatinine and thryroid-stimulating hormone.  
 
The NIA sample, which consisted of neuroleptic-treated in-patients recovering from 
psychosis, was recruited by their clinicians who made the initial diagnosis of NIA and 
excluded those with psychotic agitation. Inclusion criteria were diagnosis of NIA 
confirmed by DSM-IV (American Psychiatric Association 1994, 2000) and ability to 
co-operate sufficiently for measuring controlled rest-activity. Thus, patients who were 
excessively psychotic or had such severe akathisia that they were unable to remain 
seated for 30 min were excluded. Patients with clinically relevant somatic diseases or 
neurological disorders other than NIA were also excluded. 
 
Exclusion criteria for the healthy controls were current use of any medication and any 
self-reported clinically relevant somatic or psychiatric disorders. 
 
All subjects were male. The mean age was 34.3 years (SD 9.9, range 19-49) in the 
ASP/ADHD group, 33.3 years (SD 12.7, range 20-55) in the NIA group, and 33.8 
years (SD 12.7, range 23-56) in the control group.  
 
5.5. Asperger study 
 
Ten individuals with Asperger’s Disorder, seven males and three females, aged 21-44 
years (mean 29.8, SD 8.0), were recruited from the Helsinki Asperger Centre. 
Inclusion criteria were an age of 18-65 years and a diagnosis of Asperger’s disorder 
according to DSM-IV (American Psychiatric Association 2000). Exclusion criteria 
were major somatic diseases, past or present psychosis, current substance abuse and 
current psychopharmacological treatment. All subjects were unmedicated except one, 
who had been on stabilized thyroxin substitution since childhood. The minimum 
wash-out period for benzodiazepine-like hypnotics and melatonin was two weeks, for 
antidepressive drugs three months and for neuroleptic drugs one year. None of the 
subjects had used hypnotics regularly, and none had had long-term neuroleptic 
exposure. 
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Somatic disorders were ruled out by clinical examination and laboratory tests, 
including electrocardiogram, serum glucose, sodium, potassium, phosphorus, calcium, 
creatinine, glutamyl-transferase, thyroxine, thyroid-stimulating hormone, prolactin, 
aminotransferases, C-reactive protein, ferritin, blood sediment, complete blood cell 
count and urine screen. Past or present psychosis was excluded by a structured 
diagnostic interview, SCID (First et al. 1997a), and other axis 1 and axis 2 disorders 
were controlled for (First et al. 1997b). No current affective pathology emerged in the 
patients except in one, who fulfilled the criteria of an episode of recurrent depression. 
The detected comorbidity with anxiety and personality pathology, which is common 
in these patients, may be explained by overlapping diagnostic features (American 
Psychiatric Association 2000, Gillberg and Billstedt 2000). It is under debate whether 
these overlapping disorders, including social phobia, OCD and schizoid personality, 
should be diagnosed with Asperger’s disorder or not. A standard neurological 
examination and magnetic resonance imaging of the head were performed on all 
patients to exclude neurological pathology or disorders other than Asperger’s. Their 
cognitive level was controlled by psychometric assessment. 
 
An age- and sex-matched group of 10 healthy controls aged between 23 and 47 years 
(mean 30.8, SD 8.8) were recruited from hospital employees. Exclusion criteria for 
healthy controls were current use of any medication and any clinically relevant self-
reported somatic or psychiatric disorders. 
 
5.6. Overlap of samples 
  
ASP/ADHD study subjects included five healthy controls and five NIA patients of 
suitable age and male sex from the NIA study. 
 
Asperger study subjects included three healthy controls used in the NIA study and 
seven used in the ASP/ADHD study.  
 
Altogether, the study material consisted of a combined group of 35 healthy controls 
(mean age 41.6 years, 19 females and 16 males), a combined group of 15 NIA 
patients (mean age 36.5 years, 5 females and 10 males), 15 RLS patients, 15 antisocial 
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ADHD patients, and 10 Asperger’s disorder patients. Thus, the total number of study 
subjects was 90.  
 
 
6.  METHODS 
 
6.1. Actometry 
 
Ambulatory activity monitors of type PAM3 (IM-systems, Baltimore, USA) were 
used to record motor activity of subjects. The mode of data collection in PAM3 is 
based on digital integration (see sections 2.4.1. and 3.6.). These actometric monitors 
contain triaxial piezoelectric accelerometer sensors that react to acceleration rates 
above 0.1 g. The recorded acceleration signal is sampled as an activity count at a rate 
of 40 Hz, and the values for each sample are used to calculate the average activity 
counts within a chosen time window, 0.1 s. The time window is sufficiently small to 
allow analysis of movements within the range of EP movement disorders (see section 
2.4.3.) With the 0.1 s time window, 1 g of acceleration equals approximately 106 
activity counts. The movement index for a chosen time period is the sum of average 
activity counts for each time window included in this period.  
 
Three-channel actometry was used instead of the more usual one-channel wrist 
actigraphy because the main focus of this study was lower limb activity. Two of the 
monitors were attached to lower limbs, one to each ankle, and one monitor was 
attached to the waist (just above the navel) to record the activity of the trunk and 
whole body. The third monitor on the waist allows the relationship between lower 
limb activity and activity of the trunk to be analysed. Besides it also served as a 
reference monitor to control for the time consistency of reported and measured gross 
movements and events during nocturnal recording to exclude time periods out of the 
bed.  Actometers are small, computerized movement detectors, which do not 
influence the normal moving of the subject. Absolute movement indices were divided 
by 1000 to allow more convenient handling of the figures. Absolute movement 
indices are reported for controlled rest, because it is a fixed time period of 30 min, but 
relative movement indices are reported for nocturnal recording as the time-in-bed 
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varies individually among the subjects. Thus, the nocturnal motor activity is the 
absolute movement index for the time-in-bed divided by the minutes spent in bed.  
 
 
 
6.2. Controlled rest-activity 
 
Thirty minutes seems to be the maximum time that akathisia patients are able to 
maintain the sitting position (Rapoport et al. 1994) and is long enough for motor 
symptoms to become manifested (Barnes 1989). Moreover, it is a usual length of a 
clinical interview while simultaneously keeping the patient’s attention focused on the 
discussion. The patient is not instructed to sit still during the interview to allow 
spontaneous, natural movements. However, it is customary for a co-operative patient 
to remain seated in a medical interview even in the presence of an urge to stand up 
and walk. Because rest-activity during sitting was the measure of comparison, those 
NIA patients who were unable to maintain the sitting position for 30 min were 
excluded from the study (see sections 5.2. and 5.4.). Most often, patients who are able 
and willing to give informed consent are also sufficiently co-operative to follow this 
type of study procedure. 
 
Controlled rest-activity is recorded in a standardized setting, in which the subject is 
observed to confirm that the sitting position is maintaned. The standardized setting is 
a 30-min clinical interview in a clinical assessment room. The solid, standard chair of 
the subject is provided with a support for the back and hands and is located two 
metres from the interviewer, the clinician. The conversation with the study subject is 
characterized by a low-stress, neutral atmosphere created by open questions and 
adhering to the themes voluntarily discussed by the subject. The interview opens with 
questions about the overall health record including somatic, neurological and 
psychiatric history of symptoms, possible treatments, previous examinations and 
routine health check-ups. Next, questions about the activity rhythms of the subject are 
posed concerning daily activity, sleeping and physical training habits. Independent of 
the study group, each subject is asked about possible movement disorder or 
hyperactivity symptoms. The subject is also encouraged to talk about eating, drinking 
and smoking habits. Naturally, the subjects are aware of the actometric recording and 
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the monitors attached to their bodies, but the idea of the interview is to focus their 
attention away from the monitors and from their own movements to allow as 
naturalistic a setting as possible while maintaining a standardized and controlled 
situation. 
 
Controlled rest-activity of lower limbs (the average of right and left ankle activity) is 
the main outcome parameter. In the NIA study, only activity of the non-dominant 
ankle (left ankle) was first used for statistical comparison (Study I), because no 
significant differences in laterality were found. The non-dominant side is typically 
chosen for actometric recording (Nagels et al. 1996). Purposeful movements, which 
can mask the more pathological movement patterns, are lateralized to the dominant 
side by definition (Springer and Deutch 1993). In actometry, both qualitative and a 
small quantitative difference are present between the dominant and non-dominant 
upper limb activities (Nagels et al. 1996). However, losing data in unilateral analysis 
of motor activity may occurr, and defining motor dominance is sometimes uncertain. 
For these reasons, and to compare the results with the three following studies, the 
inter-group comparisons in the NIA study were re-analysed here with the data 
obtained from both lower limbs.   
 
The ankle-waist ratio of controlled rest-activity is a secondary outcome parameter. It 
reflects the distribution of motor activity between the trunk and lower limbs. 
Therefore, a relatively high ankle-waist ratio indicates that the emphasis of body 
activity is on the lower limbs. A high lower limb activity combined to a high ankle-
waist ratio thus indicates motor hyperactivity specific to the lower limbs. 
 
The most consistent recording sessions (30 min within a 2-hour period) were in the 
NIA and RLS studies, which represented the earliest (9 am-11 am in the former) and 
the latest (5 pm-7 pm in the latter) recording times. The subjects in the other two 
studies were recorded within these time frames, mostly in the afternoon. 
 
6.3. Day-time activity 
 
Motor activity was measured in all the subjects of the NIA study between 9 am and 
11:30 pm, and the period of controlled rest was included in the day-time recording 
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between 9 am and 11 am. Quantification of daily motor activity was performed with 
the same three-channel recording (see section 7.1.), which was also used in 
quantification of controlled rest-activity in all patient groups and of nocturnal activity 
in the RLS group. 
 
6.4. Nocturnal activity  
 
The circadian rhythm and the qualities of a sleep disorder in RLS implicated an 
assessment of nocturnal activity in addition to controlled rest-activity. The nocturnal 
activity was recorded in all subjects during the night following the recording of 
controlled rest-activity. 
 
Nocturnal activity is measured by a home-recording to obtain a naturalistic 
assessment. The subjects carried the ambulatory monitors with them at home, and the 
motor activity during time-in-bed was analysed. Subjective reports of time spent in 
bed were used to calculate the nocturnal activity during time-in-bed. Time-in-bed was 
defined as the period between going to bed to sleep and getting up in the morning. 
The time consistency of the reported periods out of bed during night-time was 
controlled for by a three-channel recording (see section 7.1.).  
 
The nocturnal recording was divided into the reported period of sleep latency and 
sleep-time in order to analyse motor activity during sleep latency and sleep, although 
subjectively reported time of sleep latency can not be considered an accurate and 
reliable measure (Spinweber et al. 1985). Thus, the main parameter was nocturnal 
activity during time-in-bed, including periods of both sleep and wakefulness. Because 
no validated symptom-severity scale was available, we chose the reported length of 
sleep latency to represent a non-actometric, indirect variable of symptom-severity or 
symptom-distress level to search for inter-correlations with the actometric data. 
 
6.5. PLM index 
 
Nocturnal PLM index for time-in-bed was defined by nocturnal actometric recording 
including both periods of sleep and wakefulness. Both PLM during sleep and while 
awake has been used as a measure of symptom severity in RLS (Allen and Earley 
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2001), and actometric quantification of PLM during time-in-bed, including both 
wakefulness and sleep, has been developed to measure symptom severity 
(Kazenwadel et al. 1995). 
 
The recommended screening criteria for PLM (Atlas Task Force of the American 
Sleep Disorders Association 1993), later applied to actometry (Kazenwadel et al. 
1995, Collado-Seidel et al. 1999), were used by an experienced blind rater to obtain 
quantitative data by calculating the PLM index. The criteria for actometric scoring of 
PLM included a duration of leg movements between 0.5 and 5 s, an inter-event 
interval between 4 and 90 s and occurrence of at least four consecutive movements 
fulfilling the above criteria. PLM index is the amount of PLM per hour of time-in-bed 
(Kazenwadel et al. 1995). The discriminating qualities of the PLM index and the 
general motor activity for time-in-bed were compared. 
 
6.6. Assessment scales 
 
The Barnes Akathisia Rating Scale (BARS) (Barnes 1989) was used for assessment of 
clinical akathisia symptoms in all subjects. The symptom severity of RLS was 
assessed by the Visual Analogue Scale (VAS), as no validated rating scales were yet 
available. A retrospective evaluation of childhood ADHD symptoms was obtained 
from Asperger patients using the Wender Utah Rating Scale (WURS), which has been 
validated as a diagnostic aid to evaluate the presence and severity of childhood 
symptoms of ADHD in adult patients (Ward et al. 1993). 
 
6.7. Haematological and biochemical assessment 
 
Basic laboratory assessment was performed on all patient groups and on the control 
group of RLS patients to exclude somatic disorders. Test batteries used were slightly 
different in each study sample (see sections 5.2.-5.5.). 
 
Assessment of serum ferritin is essential in RLS since iron deficiency is a risk factor 
for RLS and iron status is correlated with symptom severity (Aul et al. 1998, Sun et 
al. 1998).  
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6.8. Other procedures 
 
In the RLS study, all subjects filled in sleep diaries during the nocturnal actometric 
recording.  
 
In the NIA study, five of the patients were switched to an atypical antipsychotic 
(olanzapine) during the study, and the actometric recording was performed again two 
weeks after the medication change. As switching antipsychotic medication from a 
conventional to an atypical drug is a primary treatment option in NIA, a remission of 
NIA symptoms was expected. This offered the possibility to monitor the treatment 
response with both clinical evaluation (by BARS) and actometry. Furthermore, a 
comparison between symptomatic NIA and NIA in remission was performed as well 
as a comparison between NIA in remission and healthy controls. The medication 
change was based on clinical judgement.   
 
6.9. Statistical analysis 
 
Because actometric data were non-normally distributed, non-parametric statistical 
tests were used in data analysis. The statistical significance of intercorrelations in the 
data was analysed with Spearman’s test. In Studies II-IV, the inter-group comparisons 
were performed using the Mann Whitney U-test (U reported as a test value), and in 
Study III the inter-group comparison between all three groups was performed with the 
Kruskal-Wallis test (Chi-square reported as a test value).  
 
Study I, focusing on NIA, was originally analysed with a parametric t-test because 
data were assumed to be normally distributed. Later, the statistical significance of 
results was confirmed with the non-parametric Wilcoxon test for paired samples (Z 
reported as a test value), used in this dissertation, which is more suited for the non-
normally distributed, paired parameters of this study.   
Table 3 
Average actometric values of 10 patients with neuroleptic induced akathisia (NIA) and 10 healthy controls. Statistical comparison between the groups. 
 
 
 NIA    Controls   Comparison  
 Med Q1 - Q3 Range  Med Q1 - Q3 Range Z p  
MOVEMENT 
INDICES: 
         
Left ankle activity 80 55-93 29-130  0.59 0.051-2.4 0.003-4.1 -2.803 0.005 
Right ankle activity 77 65-130 23-230  1.1 0.54-4.1 0.0-4.6 -2.803 0.005 
Lower limb activity1  81 60-110 26-160  0.95 0.35-3.5 0.0015-4.0 -2.803 0.005 
Ankle-waist ratio2  2.8 2.0-3.7 1.4-4.2  0.33 0.11-0.99 0.0-2.2 -2.803 0.005 
          
 
   Average actometric values and  BARS scores of 5 NIA  patients before (symptomatic), and after the medication change (in remission).  
   BARS = Barnes Akathisia Rating Scale 
 
        NIA (symptomatic)          NIA (in remission) Comparison  
 Med       Range  Med          Range Z p  
MOVEMENT 
INDICES: 
       
Lower limb activity1   89 26-130  1.1 0.38-24 -2.023 0.043 
BARS 2 2-4  0 0-1 -2.032 0.042 
        
 
Statistics:  
Med = median, Q1-Q3 = interquartile range 
p = values for statistical difference between groups  
Z = test values for Wilcoxon paired sample test 
 
Movement index derivatives: 
1.  Mean value of  right and left ankle movement indices 
2.  Movement index of the waist divided by the lower limb activity index 
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7.  RESULTS 
 
For results, see Tables 3-7 and Figs 1-2. 
 
7.1. NIA study 
 
Lower limb controlled rest-activity was significantly higher in NIA patients than in 
healthy controls, and it discriminated the two groups with no overlap (Table 3). The  
 
ankle-waist ratio during controlled rest also significantly differentiated the NIA 
patients from controls (Table 3), but no significant differences were found in either 
lower limb activity or the ankle-waist ratio when comparing daily motor activity 
between NIA patients and healthy controls.  
 
When the five NIA patients whose medication was changed immediately after the first 
recording were compared to themselves after two weeks, in remission phase, the 
decrease of their lower limb activity was significant (Table 3). Moreover,  their 
median lower limb activity was at the level of their healthy counterparts, or even 
lower, showing no significant difference compared with controls (Table 7). 
Qualitatively, akathisia appeared in lower limb actometry as periodic, rhythmic 0.7-
1.6 Hz activity episodes increasing towards the end of the 30 min of controlled rest.   
 
The median BARS global item score of the patients was 2.5 (between 2, mild, and 3, 
moderate akathisia). Their scores ranged from 2 to 4 (marked akathisia). For those 
five patients whose medication was changed, the initial scores decreased significantly 
in remission (Table 3). The BARS scores seemed to be positively and linearly 
correlated with controlled rest-activity, but probably due to the small sample size, the 
correlation did not reach statistical significance (r=0.536, p=0.110). 
 
7.2. RLS study 
 
The higher controlled rest-activity differentiated the RLS patients from healthy 
controls significantly.  The difference remained significant when analysing both lower  
Table 4 
Average actometric values of 15 patients with restless legs syndrome (RLS) and 15 healthy controls. Statistical comparison between the groups. 
 
 
 RLS    Controls   Comparison  
 Med Q1 - Q3 Range  Med Q1 - Q3 Range U p  
CONTROLLED REST 
ACTIVITY: 
         
Left ankle activity  12 8.4-14 3.5-47   0.9 0.48-2.5 0.15-4.8 2.0 0.000 
Right ankle activity  12 8.9-18 1.8-30.0   0.9 0.40-1.8 0.12-4.4 8.0 0.000 
Lower limb activity1   11 8.4-20.3 2.8-30.0   1.1 0.43-2.8 0.21-.3.5 4.0 0.000 
Ankle-waist ratio2   1.3 0.62-2.2 0.41-6.1   0.60 0.37-1.6 0.29-6.8 70.0 0.078 
          
NOCTURNAL 
ACTIVITY: 
         
Left ankle activity 720 340-910 140-2000  48 32-150 15-290 7.0 0.000 
Right ankle activity 650 380-890 160-1300  80.4 23-180 12-280 5.0 0.000 
Lower limb activity1  650 520-860 260-1500  58 27-140 13-220 0.00 0.000 
          
PLM INDEX: 1.4 0.00-7.4 0.0-46  0.00 0.00-0.00 0.00-1.5 47 0.002 
          
          
 
Statistics:  
Med = median, Q1-Q3 = interquartile range 
p = values for statistical difference between RLS and control groups  
U = test value for Mann-Whitney U-test 
 
Movement index derivatives: 
1.    Mean value of right and left ankle movement indices 
2. Movement index of the waist divided by the lower limb activity index 
 
PLM index:  periodic limb movement index 
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limbs separately (Table 4). The median ankle-waist ratio was higher in the RLS group 
than in controls, but the difference did not reach statistical significance (Table 4). 
There was some overlap between the controlled rest activity of the RLS patients and 
the healthy controls (Table 4). The best discriminative sensitivity was 93% and 
specificity was 100% with a threshold value of 5.00. 
 
The nocturnal lower limb activity per minute was significantly higher in the RLS 
group compared with controls and the difference was significant for both lower limbs 
analysed separately (Table 4). The small laterality differences were non-significant in 
both the RLS group (Z=-0.227, p=0.820) and the control group (Z=-0.341, p=0.733). 
The nocturnal rest-activity discriminated the RLS patients from healthy controls with 
a sensitivity of 100% and a specificity of 100% when using a threshold value of 250. 
The nocturnal activity was significantly correlated (r=0.744, p<0.0005) with the 
controlled rest-activity.  
 
The median of the reported sleeping time was 388 min in the RLS group and 377 min 
in the control group, showing no significant difference between the groups (U=111.5, 
p=0.967). The sleep latency was significantly longer (U=62.5, p=0.036) in the RLS 
group (median 30 min) than in the control group (median 24 min). The length of sleep 
latency was positively and significantly (p=0.035, r=0.386) correlated with nocturnal 
activity. There was a trend towards a positive inter-correlation between sleep latency 
and controlled rest-activity, but it was non-significant (r=0.289, p=0.122). Motor 
activity during sleep-latency differentiated the RLS group from the controls 
significantly (U=4.0, p<0.0005), as did the activity during sleep (U<0.0005, 
p<0.0005). 
 
Healthy controls (n=6) with a sleep latency of 30 min or more (median 40, range 30-
90) were compared with RLS patients (n=9) within the same range (median 30). The 
nocturnal activity was again significantly (U<0.0005, p=0.001) higher in the RLS 
patients (median 715) than in the healthy controls (median 99.0) in subgroup analysis, 
and nocturnal activity still discriminated RLS patients (range 313-1510) from healthy 
controls (range 26.6-221) with no overlap. The controlled rest-activity was also 
significantly (U=2.0, p=0.002) higher in the RLS patients (median 9.66) than in 
healthy controls (median 0.863) within this subgroup.  
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The nocturnal PLM index differentiated the RLS patients from healthy controls 
significantly (table 4). The best discriminative power was obtained with the threshold 
value 0.5: sensitivity 67% and specificity 87%. The range of the healthy controls was 
totally overlapped by the range of the RLS group (table 4). The PLM index was 
positively and significantly correlated to nocturnal activity (r=0.520, p=0.003) and to 
controlled rest-activity (r=0.621, p<0.0005). There was also a positive, but non-
significant (r=0.341, p=0.065) correlation to the length of sleep latency. 
 
In qualitative analysis the typical PLM pattern fulfilling the screening criteria 
(Kazenwadel et al. 1995) was detected in 10 RLS patients and in 2 healthy controls 
during night-time and in 5 RLS patients and in none of the healthy controls during the 
controlled rest. Other type of unspecific motor activity was more predominant in both 
groups. Furthermore, a motor pattern resembling to PLM, but not fulfilling the 
screening criteria, was quite common in RLS during nocturnal recording. The 
duration of these movements were often longer than allowed by PLM criteria, 
probably caused by clustering of shorter movements into longer movement 
complexes. The considerable amount of random background activity may also have 
complicated the diagnosis of PLM patterns. 
 
During the 30 minutes of the controlled rest, the RLS group typically showed many 
random, transient, short activity intrusions of 1-10s related to changing of the pose 
and moving the legs. This was sometimes intermixed with a more continuous, 
fluctuating activity of irregular or changing rhythm and amplitude obviously 
corresponding to the motor restlessness due to uncomfortable sensations during rest. 
Just a few short, random small-amplitude activity peaks were detected in the healthy 
controls except in one subject, who showed a 30s period of continuous activity on the 
right channel while she was circling and stretching her right ankle. 
 
In clinical assessment, 8 of the RLS patients scored 2 in BARS due to their subjective 
feelings of restlessness localized to legs and an urge to move while seated. Other 7 
patients and all the healthy controls scored zero. The serum-ferritine was not 
correlated to any of the study parameters. 
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7.3. ASP/ADHD study 
 
Median lower limb rest-activity of the ASP/ADHD group was significantly higher 
than the activity of the controls (Table 5). As expected, the lower-limb activity of NIA 
patients was also significantly higher than the activity of control subjects (Table 5). 
Lower limb activity of the ASP/ADHD group fell between that of the control and the 
NIA groups. The activity range of the ASP/ADHD group was clearly discriminative 
of the control range, but some overlap occurred with the range of the NIA group 
(Table 5).  
 
Ankle-waist ratio, reflecting the emphasis of motor activity on the lower limbs, 
differentiated ASP/ADHD patients significantly from controls, and as in previous 
findings, the ankle-waist ratio also significantly differentiated NIA patients from 
controls (Table 5).  
 
When comparing the ASP/ADHD group to the NIA group, the lower limb activity of 
the former was significantly lower (U=26.0, p=0.004). The ankle-waist ratio showed 
no significant difference between  groups (U=46.0, p=0.115), although a  trend was 
found for higher ankle-waist ratios in NIA patients than in ASP/ADHD patients, 
reflecting more disturbed movement distribution in NIA patients. When comparing all 
three groups, a significant group effect was present in both lower limb rest activity 
and ankle-waist ratio (Table 5). 
 
The three ASP/ADHD patients diagnosed with current affective or anxiety disorders 
were compared with the other 12 ASP/ADHD patients: their lower limb activity did 
not differ significantly (U=13.0, p=0.470) from that of the others, nor did the ankle-
waist ratio show any significant difference. When excluding the three cases with 
affective/anxiety disorders from the comparison of the ASP/ADHD sample to the 
control group, all significant differences between the groups remained unchanged. 
 
Qualitative analysis of the actometric raw data revealed similarities between the 
ASP/ADHD and the NIA samples: 13 out of  15 patients in the ASP/ADHD sample 
demonstrated regular rhythmic activity periods of  0.85-1.80 Hz (mean 1.2 Hz, SD 
0.3), which were indistinguishable from the earlier-mentioned akathisia pattern. The  
Table 5 
Average actometric values of 15 antisocial personality disorder patients with attention deficit hyperactivity disorder (ASP/ADHD), 10 patients with neuroleptic-induced 
akathisia (NIA) and 15 healthy controls (CON). Statistical comparison of the two patient groups with controls, and comparison of the three groups. 
 
 
 ASP/ 
ADHD 
   ASP/AD
HD vs. 
CON 
 NIA    NIA  vs. 
CON 
 CON    ASP/ADHD  vs. 
.NIA vs. CON 
 Med Q1 - Q3 Range U p 1  Med Q1 - Q3) Range U p 1  Med Q1 - Q3 Range Chi 
square 
p 2 
MOVEMENT INDICES:                  
Left ankle activity  21.5 15.5-35.9 9.1-80.3 0.000 0.000   55.3 33.4 -94.6 23-129 0.000 0.000  0.84 0.14-1.68 0.06-3.3 30.0 0.000 
Right ankle activity  15.5 10.6-44.2 6.6-62.7 0.000 0.000   59.0 24.5 -82.7 16-228 0.000 0.000  0.76 0.04-2.72 0.0-.4.5 31.0 0.000 
Lower limb activity 1  19.9 14.0-36.3 13-66 0.000 0.000   57.1 43.5-83.1 20-160 0.000 0.000   0.92 0.07-1.85 0.0015-4.0 30.4 0.000 
Ankle-waist ratio2   2.01 1.00-4.15 0.23-6.7 23.0 0.000   2.73 2.22-5.20 1.4-7.4 0.000 0.000   0.55 0.16-0.79 0.02-1.0 22.9 0.000 
                  
 
Statistics:  
Med = median, Q1-Q3 = interquartile range 
p1 = values for statistical difference between ASP and CON as well as between NIA and CON: Mann-Whitney U-test (two-tailed).  
P2 = values for statistical difference between the three groups: ASP, NIA and CON: Kruskal-Wallis test. 
U = test value for Mann-Whitney U-test 
Chi square = test value for Kruskal-Wallis test 
 
Movement index derivatives: 
1.  Mean value of right and left ankle movement indices 
2.  Movement index of the waist divided by the lower limb activity index 
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frequency range of rhythmic activity in the NIA sample here (range 0.65-1.7 Hz, 
mean 1.1 Hz, SD 0.33) was almost identical. The healthy controls demonstrated no 
such pattern. ASP/ADHD had more movement episodes at the end of the controlled 
rest period, similar to akathisia patients. Unlike akathisia patients, however, the 
ASP/ADHD patients showed a considerable proportion of irregular motor 
hyperactivity among the akathisia-like patterns during controlled rest. 
 
Clinically, no qualitative difference in the restless movements between ASP/ADHD 
and NIA groups was observed. Both groups demonstrated episodic, small-amplitude, 
jerky foot movements, consisting of heel tapping on the floor and foot shaking when 
the legs were crossed. The restless movements increased towards the end of the 30 
min of sitting (controlled rest period) and were limited to the lower limbs. The 
subjects seemed to be unaware of their repetitive, monotonic movements. All subjects 
remained seated during the 30-min controlled rest period despite an urge to move 
reported by all NIA patients and the majority of ASP/ADHD patients.  
 
The median BARS score in the ASP/ADHD group was 2 (range 0-3). Nine of the 
ASP/ADHD patients scored 2 (mild akathisia) or more in BARS and would have 
fulfilled the DSM-IV criteria of NIA except for neuroleptic exposure. Three 
ASP/ADHD patients scored 1 in BARS (questionable akathisia) and another three 
scored 0, showing no signs of akathisia in clinical evaluation. However, two of the 
latter demonstrated increased lower limb activity and a rhythmic akathisia-like pattern 
in actometry. In the NIA group, the median BARS score was 3 (range 2-4), and all 
healthy controls scored 0 in BARS. The increase of BARS scores in the ASP/ADHD 
group compared with the zero level in the control group was significant (U=22.5, 
p=0.000), but the BARS scores of the ASP/ADHD group were significantly (U=23.5, 
p=0.002) lower than those of the NIA group.  
 
7.4.   Asperger study 
 
The controlled rest-activity of the lower limbs was significantly higher in the 
Asperger group than in their controls. The significant difference between the groups 
remained when both lower limbs were analysed separately (Table 6). No significant  
 
Table 6 
Average actometric values of 10 patients with Asperger’s disorder and 10 healthy controls. Statistical comparison between the groups. 
 
 
 Asperger    Controls   Comparison  
 Med Q1 - Q3 Range  Med Q1 - Q3 Range U p  
MOVEMENT 
INDICES: 
         
Left ankle activity  11 7.4-19 0.79-38  0.38 0.094-1.2 0.026-4.1 3.0 0.000 
Right ankle activity  7.6 2.7-23 0.38-37  0.85 0.011-1.3 0.00-3.3 10.0 0.002 
Lower limb activity 1  12 5.1-23 0.59-30   0.74 0.07-1.1 0.032-4.0 6.0 0.001 
Ankle-waist ratio2   2.6 2.4-4.2 1.0-15   0.4 0.2-0.8 0.02-2.2 2.0 0.000 
          
 
Statistics:  
Med = median, Q1-Q3 = interquartile range 
p = values for statistical difference between the groups  
U = test value for Mann-Whitney U-test 
 
Movement index derivatives: 
1.    Mean value of right and left ankle movement indices 
2. Movement index of the waist divided by the lower limb activity index 
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laterality differences were found. The ankle-waist ratio was significantly higher in the 
Asperger group than in their controls (Table 6). 
 
Eight of the 10 Asperger’s disorder subjects demonstrated lower limb activity (range 
5.5-30.4) above the range of the healthy controls (range 0.03-4.0), whereas the 
remaining two were within the range (Fig. 1). These eight also differed from the 
healthy controls in the qualitative analysis; they demonstrated a regular, rhythmic 
movement pattern of frequencies between 0.5 and 1.0 Hz, which was not detected in 
the controls. The rhythmic motor activity of the Asperger’s disorder subjects occurred 
in periods of 5-90 s. Those two Asperger’s disorder subjects with low movement 
indices showed random, unspecific motor activity similar to the healthy controls. The 
rhythmic movement periods detected in the Asperger’s disorder group occurred 
mostly towards the end of the 30 min of controlled rest.  
 
Three of the 10 Asperger’s disorder subjects demonstrated clinical akathisia 
symptoms, scoring 2 (mild akathisia) in BARS. Another three scored 1 (questionable 
akathisia) and the remaining four scored 0 (no akathisia). The lower limb movement 
indices for the whole Asperger’s disorder group were not significantly correlated with 
BARS scores, but the correlation did reach a significant level (r=0.76, p=0.03) for 
those eight patients whose movement indices were above the range for healthy 
controls. The median lower limb activity was 24.3 for those who scored 2 in BARS,  
while for those scoring 1 or 0, it was 6.56. The difference between those with clinical 
akathisia symptoms (BARS 2) and those without (BARS 0-1) was significant (U=0.0, 
p=0.017). The average increase of BARS scores for the whole patient group was 
significant (U=20.0, p=0.005), when compared with the zero level of the control 
group. 
 
Four of the 10 Asperger’s disorder subjects scored above 46, the cut-off point in 
WURS, suggesting a history of ADHD. Their median lower limb movement index 
was 10.3, whereas for the six subjects below the WURS cut-off point, it was 13.4. No 
significant difference (U=11.0, p=0.83) was present between subgroups. The WURS 
scores had no correlation with any of the movement indices, nor were the WURS and 
the BARS scores inter-correlated. One of the Asperger’s disorder subjects fulfilled the 
diagnostic criteria for RLS, but he reported having these symptoms infrequently, less 
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than once a month, and the symptoms were absent at the time of evaluation and 
actometric recording. This individual had the lowest movement indices, falling within 
the normal range.  
 
In conclusion, high lower limb activity differentiated the Asperger’s disorder group 
significantly from healthy controls, and the majority of Asperger’s disorder patients 
also demonstrated a specific movement pattern, which was not detected in the 
controls. 
 
7.5. Summary 
 
Controlled rest-activity was significantly increased in all patient groups compared 
with healthy controls (Table 7), discriminating NIA and ASP/ADHD patients from 
healthy controls with no overlap (Fig. 1). The rest-activity of the NIA group was 85-
fold compared with controls, and 84-fold compared with themselves in remission. The 
decrease in activity when NIA was adequately treated was significant. The NIA 
patients in the remission phase did not differ from healthy controls, showing an equal 
or even lower average activity level than their controls (Table 7). 
 
The activity of the ASP/ADHD group was 22-fold compared with controls but was 
significantly lower than the activity of the NIA group (Table 7). The Asperger’s 
disorder group showed a 16-fold increase of activity compared with controls, and the 
RLS group showed a 10-fold increase of activity. The increase of nocturnal activity in 
the RLS group was 11-fold compared with controls, and nocturnal activity, unlike 
controlled rest-activity, discriminated the RLS patients from controls with no overlap 
(Table 7).   
 
When analysing the differences in controlled rest-activity, including all patient groups 
and all healthy controls, a significant group effect was present using the Kruskal-
Wallis test (chi-square=72.02, p<0.0005). The highest activities were found in NIA 
patients, and next, in descending order, were the ASP/ADHD, Asperger’s disorder, 
and RLS patients, while the lowest activity was measured, expectedly, in the healthy 
controls (Fig. 1). 
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Table 7:  Summary of results. 
 
CRA=controlled rest-activity; NIA=subjects with neuroleptic-induced akathisia; 
RLS=subjects with restless legs syndrome; ASP/ADHD=subjects with antisocial 
personality disorder and attention deficit hyperactivity disorder. For statistical test 
values, see section 6.9. 
 
Study Comparisons / 
Parameters 
Patients Patients Controls U/ Z/ Chi 
square 
  P 
       
       
I NIA  vs. Controls 10 - 10   
 
CRA (median) 80.6 - 0.95 -2.803 0.005 
 
      
 
NIA vs.  NIA 
remission 
5 5 -   
 
CRA (median) 88.6 1.06 - -2.023 0.043 
 
      
 
NIA-remission vs. 
Controls 
5 - 5   
 
CRA (median) 1.06 - 3.34 -1.214 0.225 
 
      
 
      
II RLS vs.  Controls 15 - 15   
 
CRA (median) 10.9 - 1.05 4.0 <0.0005 
 
Nocturnal Activity 
(median) 
650 - 58.3 <0.0005 <0.0005 
 
      
 
      
III ASP/ADHD vs.  
Controls 
15 - 15   
 
CRA (median) 19.9 - 0.92 <0.0005 <0.0005 
 
      
 
ASP/ADHD vs.  NIA 15 10 -   
 
CRA (median) 19.9 57.1 - 26.0 0.007 
 
      
 
NIA vs.  Controls 10 - 15   
 
CRA (median) 57.1 - 0.92 <0.0005 <0.0005 
 
      
 
ASP/ADHD  vs. NIA 
vs. Controls 
15 10 15 30.4 <0.0005 
 
      
 
      
IV Asperger vs.  Controls 10 - 10   
 
CRA (median) 12.1 - 0.74 6.0 0.001 
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Qualitative differences were also found in the movement patterns between groups; 
NIA, ASP/ADHD and Asperger’s disorder patients showed rhythmic, episodic 
activity increasing towards the end of the 30-min recording time. The frequency range 
of rhythmic activity was 0.5-1.8, and frequencies close to 1 Hz were the most 
prominent. This finding was clearest in the NIA group; in the other two patient 
groups, rhythmic, regular activity was intermixed with irregular and non-rhythmic 
activity.  This type of activity was not detected in healthy controls or in RLS patients. 
Instead, the RLS group demonstrated a PLM pattern occurring at 5- to 90-s intervals, 
which is considered to be a pathognomonic feature of RLS (IRLSSG 1995, 
Kazenwadel et al. 1995).  
 
Figure 1   (on the right) 
 
A graphic illustration of quantitative motor activity during controlled rest (controlled 
rest-activity) of each study group. NIA=neuroleptic-induced akathisia; 
ASP/ADHD=antisocial personality disorder with attention deficit hyperactivity 
disorder; Asperger=Asperger’s disorder; RLS=restless legs syndrome; 
Controls=healthy persons. 
 
Figure 2   (page 76) 
 
A graphic illustration of motor activity recorded during 30 min of controlled rest and 
movement patterns focused on the left ankle. A typical subject from each patient 
group (male, about 30 years) and two control subjects were selected. 
 
The entire recording of controlled rest-activity, while the subject is sitting for 30 min 
is presented in the 1st column. The last 5 min of the controlled rest is presented in the 
2nd column. A 10-s focus of the last 5 min, including movements, is presented in the 
3rd column, except for control subjects, who displayed no movements during the last 5 
min. For them, a 10-s focus of the highest activity throughout the recording is 
presented. 
 
The focused time periods are indicated with spotted areas and arrows. 
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8. DISCUSSION 
 
Motor activity during controlled rest was increased in each of the neuropsychiatric 
disorders studied here. Diagnosis had a significant effect on rest-activity. The highest 
increase in activity was observed in NIA patients, and the lowest in RLS patients. 
Controlled rest-activity discriminated both NIA and ASP/ADHD patients from 
healthy controls with no overlap. Each patient group also showed qualitative 
differences in motor activity compared with controls. NIA, ASP/ADHD and 
Asperger’s disorder groups shared similarities in movement pattern, while RLS 
patients showed a distinctive pattern. 
 
8.1. Motor characteristics of NIA 
 
A marked increase of rest-activity and a pathognomonic movement pattern was seen 
in NIA patients when motor activity was measured in a standardized setting in which 
patients sat for 30 min. Akathisia, by original definition, means “not to sit”, which is 
objectively demonstrated in actometry as an episodic, rhythmic motor restlessness 
increasing towards the end of the 30-min period. The predominant occurrence of 
movement episodes at the end of the rest period refers to an intensified urge to move 
during prolonged immobilization, or to a diminishing of the initial ability to suppress 
movements. These motor symptoms were accompanied by subjectively reported inner 
restlessness and an urge to move intensified by immobility. Contrary to controlled 
rest-activity, the daily motor activity level of NIA patients was not increased 
compared with healthy controls, which is possibly explained by the relative 
passiveness and limited activities of hospitalized patients. It seems that a greater 
amount of purposeful motor activity in work and leisure increases the day-time 
activity levels of healthy controls so that they are as active during the daytime as the 
NIA patients.  
 
Although the results indicate that controlled rest-activity is clearly discriminative of 
NIA, the study setting can be criticized for using healthy persons as controls for 
hospitalized schizophrenic NIA patients instead of comparing schizophrenic in-
patients with NIA with similar patients without NIA. This raises the question that 
could the increased rest-activity actually be due to schizophrenia instead of being a 
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consequence of NIA. However, the study of Gardos et al. (1992) shows that the 
baseline activity in schizophrenics is not higher than in healthy persons, in parallel 
with our findings. Thus, the high rest-activity of schizophrenic NIA patients in our 
study is likely mostly due to NIA rather than to schizophrenia. A standardized setting 
will typically elicit NIA symptoms and exclude the effect of purposeful daily 
activities on motor activity levels. The decrease of rest-activity to the level of healthy 
controls when NIA is treated further confirms that the increased rest-activity is really 
a phenomenon related to NIA. As the positive psychotic symptoms were already 
clinically stabilized at the inclusion phase, and the possible amelioration of negative 
symptoms would probably take longer than 2 weeks, the reduction of hyperactivity is 
unlikely to be explained by a marked change in psychotic symptoms.    
 
The qualitative finding of an abnormal actometric movement pattern similar to the 
pattern previously described in NIA (Braude et al. 1984, Rapoport et al. 1994) also 
supports the value of controlled rest-activity as a diagnostic measure in NIA. 
 
Actometry is probably more sensitive in detecting abnormal motor activity in NIA 
than the routine clinical assessment, especially in atypical forms of NIA with 
diagnostic problems such as hypokinetic akathisia (Tuisku et al. 2000). Hypokinetic 
akathisia is a form of subjective akathisia in which the clinical motor symptoms of 
akathisia are masked by the hypokinesia related to neuroleptic-induced parkinsonism. 
Van Putten and Marder (1986) used the term “subjective akathisia” for the first time 
to describe akathisia without observable restless movements. They postulated that 
mild akathisia may not be manifested as motor symptoms, particularly when a patient 
has a co-existing akinesia. The subjective component seems to be a fundamental and 
primary feature of akathisia (Van Putten 1975, Munetz 1983). Subjective akathisia 
poses a diagnostic challenge (Chung and Chiu 1996, Tuisku et al. 2000) because the 
DSM-IV criteria require objective motor restlessness (American Psychiatric 
Association 2000). Furthermore, the rating of subjective akathisia by BARS may be 
impossible (Tuisku et al. 2000). Despite its wide use among clinicians and the 
practicality and validity in classical akathisia, BARS disregards the richness of 
clinical features (Cunningham Owens 1999, Tuisku et al. 2000). 
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8.2. Differential diagnostics of NIA and RLS 
 
Historically, because of the confusion between akathisia and RLS (Sachdev 1995a), 
the differential diagnostic features in actometry are of interest. In RLS, an increase in 
controlled rest-activity similar to NIA occurred, but it was more modest. In addition, 
some overlap was present between the range of healthy controls and that of RLS 
patients. RLS patients did not demonstrate the increased ankle-waist ratio typical of 
akathisia patients. Furthermore, the movement pattern in RLS was completely 
different from that in NIA, consisting of irregular, transient or fluctuating motor 
activity and sometimes PLM, in contrast to the clearly episodic, regular, rhythmic 
bursts of activity in NIA. The qualitative analysis of the movement pattern seems to 
be helpful for differential diagnosis between NIA and RLS. The PLM pattern 
recorded in the setting of controlled rest during wakefulness was not surprising 
because PLM are described to manifest not only in sleep but also during wakefulness 
in RLS (IRLSSG 1995). In fact, a restriction of the analysis to PLM occurring in sleep 
may result in an underestimation of the actual frequency of PLM (Kazenwadel et al. 
1995).  
 
8.3. Symptom severity of RLS 
 
The nocturnal motor activity during time-in-bed differentiated RLS patients from 
healthy controls, showed good discriminative qualities and was better than the PLM 
index, which is a widely used measure of symptom severity and a diagnostic marker 
of RLS (Montplaisir et al. 1998, 1999). The specificity (67%) and sensitivity (87%) of 
the PLM index are close to those reported previously (68-81% and 73-81%, 
respectively) (Montplaisir et al. 1998). Nocturnal rest-activity proved to be the best 
actometric marker of RLS. The superiority of nocturnal activity over controlled rest-
activity in discriminating RLS symptoms is probably due to the typical circadian 
rhythm of RLS. However, the discriminative power of these measures would probably 
be reduced in comparisons with other sleep disorders or disorders related to abnormal 
motor function. Further studies are needed to show the differential diagnostic value of 
actometric nocturnal activity.  
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The benefit of analysing a sample of diagnostically pure RLS patients is that any 
actometric difference in comparison with the control group can now be expected to be 
due to RLS or RLS secondary effects such as insomnia. In theory, insomnia may have 
a direct effect on nocturnal activity, but not on the controlled rest-activity. To exclude 
the possibility that insomnia might explain the findings attributed to RLS, a further 
analysis was performed with a subgroup of RLS and control subjects with equal sleep 
initiation difficulties. In this analysis, the inter-group difference in nocturnal activity 
remained significant and the nocturnal activity still discriminated the RLS patients 
from healthy controls with no overlap. The control sample, mainly consisting of 
nurses working in shifts, did not represent ideal sleepers, although they reported no 
symptoms of major sleep disturbances on admission to the study.  
 
A subsequent treatment intervention study (Tuisku et al. 2002b) with the same RLS 
patients further supports the value of actometric nocturnal activity and the controlled 
rest-activity as an adequate, quantitative measure of symptom severity. The treatment 
response to pramipexole, a drug with proven efficacy in RLS (Montplaisir et al. 
1999), was objectively demonstrated as an 81% decrease of average nocturnal activity 
and a 68% decrease of average controlled rest-activity to the range of healthy 
controls. The decrease of both actometric parameters was significant. The subjective 
measures of symptom severity also decreased significantly, with the average decrease 
being 50%. Considering the results with this RLS sample and previous reports (Mills 
et al. 1993, Hening et al. 1999a, Montplaisir et al. 1999, Allen and Earley 2001), 
nocturnal quantitative actometry appears to be a more naturalistic, objective and 
quantitative assessment method for treatment trials than the previously used methods. 
 
8.4. Akathisia-like hyperactivity in antisocial violent offenders with ADHD 
 
The antisocial violent offenders with ADHD demonstrated motor hyperactivity at rest 
when compared with healthy controls. The lower limb motor activity in ASP with 
ADHD was lower than in NIA, but no significant difference was found in the ankle-
waist ratio between the two patient groups. The emphasis of the hyperactivity was 
more on the lower limbs than on the trunk in both ASP with ADHD and in NIA. The 
majority of the ASP patients with ADHD demonstrated clinical akathisia symptoms 
(assessed by BARS) and a typical akathisia pattern in qualitative actometric analysis: 
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repetitive, rhythmic movement episodes of similar frequencies with a predominant 
occurrence of movement episodes at the end of the controlled rest period.  The 
comorbidity between ADHD and RLS (Picchietti et al. 1999) suggests that the 
increased rest-activity in ADHD might be related to RLS rather than to akathisia. 
Qualitative analysis, however, gives evidence in favour of akathisia. The appearance 
of the NIA pattern and the increased movement indices in the ASP group are unlikely 
to be explained by psychopathology other than ADHD in ASP since current drug 
abusers were excluded and only three ASP patients were diagnosed with current 
affective and anxiety disorders. Their movement indices showed no significant 
differences in comparison with other ASP patients. 
 
Aggressive behaviour is of primary clinical importance in ASP. The role of ADHD in 
antisocial development seems to central because conduct disorder, another precursor 
of ASP (McCracken et al. 2000), seems to be part of severe ADHD (Thapar et al. 
2001). Furthermore, poor impulse control, an important prerequisite of aggressive 
behaviour, is an essential feature in both ADHD and conduct disorder (American 
Psychiatric Association 2000). The pharmacological treatment of aggression in  
ADHD includes the same options that are used in NIA, which suggests similarities in 
their pathophysiological mechanisms: aggression related to ADHD seems to respond 
to propranol and to clonidine (Mattes 1990, Pliszka et al. 2000), which are also the 
primary and secondary treatment option, respectively, in NIA (Taylor et al. 2001). As 
akathisia has been related to aggressive behaviour (Ratey and Gordon 1993, Stubbs et 
al. 2000) and akathisia-like motor findings have been observed here in violent 
offenders with ADHD, the possible role of akathisia-like mechanisms behind the 
aggressiveness of ADHD patients must be considered. Understanding the 
pathophysiology of akathisia may create new pharmacological hypotheses for treating 
aggression in ADHD. 
 
The quantitative increase of rest-activity, in the absence of qualitative findings, would 
most naturally be related to ADHD itself, rather than to akathisia, because motor 
hyperactivity is an important diagnostic sign and a marker of symptom severity in 
ADHD based on the findings of this study placed in the context of previous studies 
(Halperin et al. 1992, Reichenbach et al. 1992). The qualitative finding of a rhythmic 
activity pattern may also be a primary feature of ADHD unrelated to NIA, despite the 
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apparent actometric similarities and clinical akathisia symptoms in BARS evaluation. 
Actometry proved to be more accurate than the normal clinical evaluation in detecting 
qualitative differences in movement patterns between the ASP/ADHD and NIA 
groups. 
 
Not all the hyperactivity during rest can be attributable to akathisia in ASP/ADHD 
patients because these subjects also show a considerable amount of irregular, non-
rhythmic activity, unlike NIA patients. The finding of a NIA pattern intermixed with 
an increased amount of non-specific activity suggests that two distinct phenomena 
explaining the quantitative increase of rest-activity may co-exist: general 
hyperactivity as the core symptom of ADHD and a more stereotyped activity related 
to akathisia. Independent of the underlying aetiology, the hyperactivity measured by 
actometry decreases with adequate treatment of ADHD (Porrino et al. 1983b), thus 
being an important indicator of symptom severity. 
 
8.5. Abnormal motor activity in Asperger’s disorder 
 
For Asperger’s disorder, no previous reports of objective quantification of motor rest-
activity are available. The key finding in this study was the increased motor activity at 
rest and rhythmic movement patterns differentiating the Asperger’s disorder patients 
from healthy controls. The detected hyperactivity appeared to be specific to the lower 
limbs since the ankle-waist ratio in the Asperger’s disorder group was clearly higher 
than in the control group. These quantitative findings resembled the findings in NIA, 
and qualitative analysis revealed a rhythmic, periodic movement pattern similar to 
NIA in terms of frequency and timing. There were, however, clear differences 
between Asperger’s disorder and NIA; the former exhibited less regularity of rhythm 
and amplitude, a smaller number of movement periods and more variation in 
movement patterns than the latter.  
 
The majority of the Asperger’s disorder patients were clearly hyperactive according to 
measurements, but two individuals fell within the range of the control subjects, 
showing very low activity. This may reflect the heterogeneity of our study sample, the 
heterogeneity of Asperger’s disorder in general or two extremes on the spectrum of 
abnormal motor activity similar to the hyperactivity and hypoactivity reported in 
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autism (Gillberg and Billstedt 2000). The eight patients with increased motor activity 
also displayed qualitative similarities to NIA. Their clinical akathisia symptoms and 
actometric findings were inter-correlated, providing further evidence for the akathisia-
like phenomena in Asperger’s disorder. The finding of lower limb motor hyperactivity 
in Asperger’s disorder cannot be explained by comorbid ADHD symptoms, as no 
correlation was found between WURS scores and activity levels, nor was there any 
difference between subjects with or without a history of ADHD according to WURS.  
Clinical RLS appeared in only one of the Asperger’s disorder patients, offering no 
explanation for the motor hyperactivity findings.  
 
Our results suggest mild, idiopathic akathisia in Asperger’s disorder patients. The 
pathophysiology of NIA is related to D2 dopamine receptor occupancy of 
antidopaminergic drugs in the basal ganglia (Farde et al. 1992), but according to 
histochemical studies, the limbic, cingulate cortex is also involved in the 
pathophysiology (Ohashi et al. 1998). A dysfunction in these dopaminergic circuits 
may also be responsible for the neuroleptic intolerance in autism and Asperger’s 
disorder, as there is already evidence of dopaminergic dysregulation, basal ganglia 
abnormalities and metabolic hypofunction of the cingulate cortex in autism (Jacobson 
et al. 1988, Ernst et al. 1997, Haznedar et al. 2000). The hypothesis of idiopathic 
akathisia in Asperger’s disorder is further supported by the hyperactivity and 
irritability symptoms in autism which respond to clonidine (Jaselskis et al. 1992, 
Fankhauser et al. 1992), one of the treatment options in NIA (Adler et al. 1987, Miller 
and Fleischhacker 2000), and the clinical vulnerability to neuroleptic-induced 
movement disorders (Campbell et al. 1997, Scahill and Koenig 1999). 
 
Instead of being a sign of idiopathic akathisia, the increased rest-activity may simply 
be a motor manifestation of a hyperactive subtype in autism (Gillberg and Billstedt 
2000), and the rhythmic pattern may be a manifestation of stereotypic movement 
related to autism itself rather than to akathisia. It is also possible that the rhythmic, 
involuntary stereotypies encountered in neuropsychiatric disorders, including 
akathisia, all belong to the same continuum of clinical manifestations of basal ganglia 
pathophysiology (Tan et al. 1997). The akathisia-like hyperactivity in most patients 
and the hypoactivity in two patients, may be clinical correlates of akathisia and 
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hypokinesia of Parkinson’s disease since there are parkinsonian features in autism 
(Vilensky et al. 1981).    
 
8.6. Methodological questions  
 
8.6.1. Controlled rest-activity 
 
Controlled rest-activity seems to more specific an indicator of abnormal motor 
activity than the measurement of diurnal activity in hyperactive neuropsychiatric 
disorders, at least in NIA, RLS and ADHD. It also offers higher comparability than 
measuring diurnal activity because the environment and the situation is the same for 
all subjects during measurements of controlled rest-activity. The ideal time of day for 
measuring rest-activity, may not, however, be the same for all neuropsychiatric 
disorders, as they have different diurnal activity rhythms (Porrino et al. 1983a, Hening 
et al. 1999b, Poyurovsky et al. 2000). Variation in the recording time, on the other 
hand, reduces the comparability of different disorders. A possible association between 
time of day and the main differences between the groups when comparing Studies I-
IV was controlled for by Spearman’s correlation test, which showed no significant 
association between the time of recording and controlled rest-activity.  
 
Time of day for actometric recording is especially important in RLS, in which the 
symptoms follow a specific diurnal rhythm. However, no correlation between 
recording time and activity level was found within this group, probably because the 
time of recording for all subjects and their controls in the RLS study was limited to 
within two hours. As both motor symptoms and subjective discomfort peak at 
midnight (Hening et al. 1999b), the recording time (5 pm-7 pm) may have led to an 
underestimation of motor hyperactivity in RLS patients. A later recording time of 
controlled rest-activity would thus have yielded a more dramatic increase of activity 
as compared with controls, but choosing a night-time recording instead of a day-time 
would have changed the naturalistic setting into an unnaturalistic one: it is more usual 
to sit in a medical interview during the daytime unless there is an emergency case. A 
night-time recording would also have reduced the comparability of RLS subjects with 
the other study populations. During the night, dopamine secretion is lower than during 
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the day, which probably would have an effect on rest-activity (Sowers and Vlachakis 
1984). 
 
The recording time at noon for NIA patients and their controls in Study I is not ideal 
either because NIA and other neuroleptic-induced EP movement disorders show a 
worsening of symptoms in the afternoon for an unknown reason (Poyurovsky et al. 
2000). Thus, assessment during the first half of the day may lead to an 
underestimation of their severity (Poyurovsky et al. 2000). The ideal recording time 
for ADHD patients is unknown. In a naturalistic actometric study, these individuals 
displayed hyperactivity regardless of the time of day (Porrino et al. 1983a). In autistic 
disorders, even less information is available concerning the diurnal rhythm of motor 
activity, which may be related to problems of compliance and tolerance in these 
patients with long-term use of activity monitors (Hering et al. 1999).  
 
The normal circadian activity recorded in healthy persons peaks in the afternoon 
(average acrophase at 2:50 pm) and is markedly attenuated between 11 pm and 7 am 
(Brown et al. 1990). There are, however, large variations in the activity phases 
between healthy individuals (Binkley et al. 1993). The main interest of this study was 
not diurnal activity rhythm, but the standardized day-time rest-activity in 
neuropsychiatric disorders with hyperactivity or other motor symptoms, although 
individual and population-specific diurnal activity rhythms may have had an effect on 
results. 
 
The main methological aim of the study was to create as naturalistic and as 
standardized an actometric method to measure activity in physical rest as possible. 
Compared with previous diurnal and day-time activity recordings with ambulatory 
monitors, the controlled rest-activity method is more standardized, and compared with 
more accurate and more standardized laboratory studies, it is more naturalistic. The 
suggested immobilization test, created by Montplaisir et al. (1998) to measure motor 
symptoms of RLS by EMG, is based on the same idea as controlled rest-activity: to 
measure lower limb rest-activity while the patient is sitting still. The former is a more 
standardized method, but the setting is more unnaturalistic, and presumably limits the 
spontaneous movement of the subject in response to unpleasant leg sensations. In 
addition, the instructions given and the laboratory setting direct the attention of the 
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subject to the measuring procedure. As the EMG electrodes make direct skin contact 
with the subject in connecting him or her to a computer system by wires, they are 
likely to disturb the subject more than the ambulatory actometric monitors attached 
around the limbs on top of clothing. 
 
A method, comparable with measuring controlled rest-activity in this study, which 
utilizes ambulatory actometry by applying it in a controlled and standardized setting, 
has been presented by Tulen et al. (2001). They quantified abnormal, involuntary 
movements of the head of patients with Tourette’s disorder during a naturalistic 
interview and other situations. A standardized, controlled observation period has also 
been created by Fann et al. (1977) for accelerometric quantifying of the spontaneous 
motor activity during rest in TD patients. In this method, the subject is described to sit 
relaxed in a chair for evaluation of the resting condition, and the recording sites are 
ankles, wrists and chin. 
 
In general, better standardization seems to be acquired at the cost of losing the 
naturalistic character of the study setting. Natural sciences applied to human subjects 
confront the eternal dilemma of a more generalizable, reductive approach or 
consideration of the natural specificity of the subject. Clinical studies in medicine 
often represent less standardised observation of the subject instead of using rigorously 
experimental, externally manipulated settings (Alanen 1989).   
 
8.6.2. Comparability and properties of actometry 
 
Actometric data obtained from different commercial applications are not comparable 
as the modulation, integration and recording of signals is different. The output data is 
generally referred to by the term “activity counts”, which are not equivalent between 
different types of activity monitors (Gorny and Allen 1999). Even within the same 
type of actometric monitors, variations in the numerical activity counts and graphic 
output data may occur unless properly and regularly calibrated. This reduces the 
generalizability of actometric findings obtained with different activity monitors, and 
no “normal ranges” or “pathological ranges” can be given. Thus, the relative 
quantitative differences between groups are relevant and generalizable, but not the 
actual numerical values. Acceleration quantified as “activity counts” does not 
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represent an absolutely defined physical measure, or unit, and can be criticized for 
being an artificial, constructed quantity. Philosophically, however, all quantities can 
be considered as scientific, abstract constructions, which are merely used for 
measuring essential, non-quantitative qualities and relations of reality (Niiniluoto 
1984). 
 
Activity counts, although not representing exact units, can be approximately equalized 
to units of gravity. Future studies should seek to equate the output from the different 
monitors to a common unit of gravitational force so that all monitors can be more 
readily compared (Welk 2002). With the actometric method of this study, 1 g of 
gravitation roughly equals 106 activity counts when using the time window 0.1 s 
(Spiro 2002). The digital integration mode of data collection (see section 3.6.) in 
PAM3 type monitors used in this study allows the waveform of the movements to be 
virtually reconstructed, and unlike other methods, allows the amplitude of movements 
to be taken into account (Gorny and Allen 1999). The graphic output of the digital 
integration method is suitable for qualitative analysis of movements to, for example, 
diagnose low-amplitude, hypokinetic tremor or identify series of PLM. The digital 
integration method used in this study is the most recently implemented actometric 
method (Spiro and Spiro 2001).  
 
The time window of activity monitors can be chosen according to its purpose. The 
smaller the time window, the higher the time resolution of the movement. 
Accelerations of the human body are typically less than 10 Hz (Welk 2002). The 
smallest time window available in PAM3 monitors (0.1 s) was chosen to be able to 
distinguish movements within the range of EP movement disorders (see sections 
2.4.3.). Because of the limited memory capacity of these monitors, choosing a smaller 
time window shortens the maximal time of continuous recording (14.5 hours in PAM3 
with this time window). In diurnal recordings, the activity rhythms are typically 
measured with a larger time window of 5 min (Binkley et al. 1993) or 15 min 
(Virkkunen et al. 1994), which is suitable for long-term quantification of motor 
activity. By contrast, the qualitative analysis of movement patterns requires use of a 
small time window with a higher frequency rate of measurement than the frequency of 
the motor phenomenon to be measured. 
 
 88 
Within a study, the test-retest reliability of accelerometry in standardized settings 
seems to be good (Reichenbach et al. 1992, Moe-Nilssen 1998), and the abnormal 
movement patterns detected in NIA, for example, are reproducible (Rapoport et al. 
1994). The lower limb rest-activity of RLS patients while sitting showed no 
significant differences between EMG recordings of two successive days (Hening et al. 
1999b). In our study, the reliability of the measurements was not controlled for. A 
repeated nocturnal recording in the RLS sample might have been useful for 
adaptation, which is a usual procedure at least in more invasive sleep studies such as 
those using polysomnography. To answer the question of whether the possible 
disturbing effect of ambulatory monitors may have worsened the RLS symptoms, the 
subjective experience of symptom severity during the last two weeks and during the 
actometry (reported as VAS scores) were compared. No significant worsening of 
symptoms at the time of actometric recording was observed, which is in accordance 
with the comments of the patients about wearing the ambulatory monitors.  
 
Random variation of accelerometric data can be divided into biological (intra-
individual) and analytic variation related to recording process (Dale et al. 2002). The 
use of triaxial accelerometers and standardization of their position on a participant 
reduce the unwanted variability of the data (Welk 2002). 
 
8.6.3. Assessment of clinical akathisia symptoms by BARS 
 
BARS has been created and validated for clinical evaluation of DIA (Barnes 1989). It 
has established statistical properties and strong face validity in NIA (Cunningham 
Owens 1999). The use of BARS for purposes other than assessment of DIA is 
questionable. It was used in these four studies for clinical screening and assessment of 
possible akathisia symptoms in hyperactive disorders other than DIA. In these studies, 
the informational value of BARS lies in supporting the akathisia-like, objective 
actometric findings. The statistically significant differences in BARS scores between 
healthy controls and each of the patient groups in our studies do not necessarily 
indicate a clinical significance because the zero level of healthy controls compared 
with unspecific restless symptoms (scoring 1 in BARS global scale) easily produces a 
statistically significant difference between groups. The score 1 in the BARS global 
scale is defined as “questionable akathisia”. Score 2 indicates “mild akathisia”, which 
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is clinically more relevant. This score, however, does not require typical motor 
symptoms of akathisia, and thus, cannot be concluded to indicate akathisia in RLS, 
which may present with similar subjective symptoms and unspecific motor 
restlessness as described for score 2 (Barnes 1989). As the objective motor symptoms 
of akathisia were missing in both actometric and clinical assessment of RLS patients, 
it is reasonable to conclude that these individuals did not display akathisia despite the 
statistically significant increase in BARS scores. 
 
The clinical significance of BARS in classical NIA fulfilling the diagnostic criteria of 
DSM-IV is indisputable, but the clinical significance may be reduced in atypical 
forms of neuroleptic-induced akathisia (see section 8.1.) and is probably reduced in 
other forms of akathisia. In the ASP/ADHD group, however, it is possible that BARS 
actually measured akathisia symptoms because a majority of the patients scored 2 or 
more and would have fulfilled the DSM-IV criteria of NIA except for neuroleptic 
exposure. The heterogeneity and small size of the Asperger group produces 
difficulties in interpretation of results, but those patients with clinical akathisia 
symptoms assessed by BARS also showed more actometric evidence of akathisia than 
those without. The use of BARS in assessment of hyperactivity symptoms other than 
NIA may be clinically relevant in some disorders (Barnes 2001), but scientific 
conclusions should be drawn with caution.     
 
8.6.4. Characteristics of subjects 
 
The representativeness of the NIA sample is limited to hospitalized patients diagnosed 
with schizophrenia spectrum disorders who were able to comply with the study 
procedures. During patient recruitment one NIA patient was excluded because of such 
severe NIA that he was unable to remain seated for the 30-min recording time. 
Another NIA patient was excluded, because he became so paranoid and agitated about 
the actometric monitors that he was not able to finish the interview. Thus, the most 
psychotic patients and those with the most severe NIA were not represented in this 
sample. The average clinical symptom severity assessment by BARS was 2.5, which 
is between mild and moderate akathisia. The most severe forms of NIA were probably 
unusual on the wards serving as recruitment channels since such patients typically 
receive immediate treatment for akathisia. Even if the differential diagnosis is 
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complicated, their psychomotor agitation is often quickly treated with 
benzodiazepines. The NIA patients of this study represented a symptom severity 
range from mild to marked akathisia. They may benefit more from diagnostic support 
and symptom severity monitoring offered by actometry than the more severe 
emergency cases. This sample was also selected with respect to comorbidity with 
parkinsonian side effects, which were excluded (see section 5.2.). The comorbid cases 
may represent another variant of akathisia with a different pharmacological profile 
(Fleischhacker et al. 1990, American Psychiatric Association 1997, Taylor et al. 
2001). 
  
The RLS sample did not consist of clinical patients, but readers of a monthly health 
journal, which served as the recruitment channel. The volunteering RLS patients were 
initially screened by a telephone interview for a preliminary check of inclusion and 
exclusion criteria. Of the 22 candidates invited to participate in the study, seven were 
excluded based on clinical examination; out of which three for purely somatic 
reasons, two for purely psychiatric reasons and two for both reasons. The somatic 
exclusions were hypertonia and migraine requiring immediate medication, recovery 
phase of meningitis and clinical orthopaedic problems. The psychiatric exclusions 
were depressive disorders and a cyclothymic disorder. Possible axis 2 diagnoses were 
also controlled for by SCID (First et al. 1997b), although they were not considered 
exclusion criteria. None of the RLS patients included in this study exhibited any 
personality pathology according to SCID assessment. 
 
The recruitment channel of RLS patients may have skewed the male-female ratio, 
which was 1:14 in this study sample. This does not match the reported ratio in 
epidemiological studies, which ranges from equal prevalences to slightly higher 
prevalences in women (Phillips et al. 2000, Ulfberg et al. 2001a, 2001b). Family 
history was positive in at least nine of the patients, and the proportion of a hereditary 
compared with a non-hereditary form of idiopathic RLS was slightly higher than 
reported in a large population (Winkelmann et al. 2000). The recruitment channel may 
also explain the better health habits of RLS patients than their controls, who were 
mostly nurses working in shifts and possibly experiencing relatively high stress levels 
due to the increasing working load in health care. More cigarette smoking, alcohol 
consumption and caffeine intake was reported in the control group, but because of the 
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unreliability of subjective reporting and non-standardized collecting of data, no 
conclusions can be drawn. However, it is likely that unhealthy habits do not explain 
the hyperactivity findings in the RLS group. This sample of RLS patients is not 
representative of the general RLS population, as it is mostly female with healthy 
living habits, suffering from considerable and frequent RLS symptoms in the absence 
of psychiatric or somatic comorbidity.  
 
The ASP/ADHD group is not representative of either ADHD or ASP alone, and 
furthermore, is likely to represent the most severe type of ASP due to a history of 
violent criminality. This group is quite representative of violent offenders undergoing 
a court-ordered mental status examination, as they are random, consecutive cases. 
Only one refusal and one exclusion because of prescribed teophyllamine medication 
were made in this sample of violent offenders. The history of heavy drinking, drug 
abuse and frequent, subclinical head traumas was so common in this sample that these 
factors are likely to have an effect on results. Comorbidity with substance abuse 
disorders and their sequelae cannot be avoided without ending up with an 
unrepresentative sample. 
 
The group of Asperger subjects comprised patients of the Helsinki Asperger Centre 
who were recruited by their clinicians. This is a clinic to which patients with a 
tentative diagnosis of Asperger’s disorder are referred from all parts of Finland for 
further neuropsychiatric examination to re-assess the diagnosis. Because of the strict 
exclusion criteria, the study sample is not a random sample of all diagnosed 
Asperger’s disorder patients but consists of non-medicated patients with no need for 
current psychiatric or other pharmacological treatments. The representativeness of the 
sample may also be reduced by possible difficulties in identifying the disorder in basic 
health care systems. The skewed male-female ratio is in accordance with ratios 
reported in epidemiological studies (Gillberg 1998b). 
       
The overall representativeness of healthy controls in this study is reduced by their 
recruitment channel: they were hospital employees including students, cleaners, 
technicians, social workers, office clerks, doctors and nurses. They may be healthier 
than the general population because of their exclusion criteria; however, their 
subjectively reported health was not systematically controlled for, except by 
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laboratory tests (see sections 5.2.-5.5.). The controls may have been more aware of 
the study purposes and the method of measuring controlled rest-activity than the 
patients. 
 
The comparability between all the study groups is lowered by different age and sex 
distributions: the youngest were the Asperger patients (mean age 29.8 years) and the 
oldest were the RLS patients (mean age 50.3 years), while the mean ages of the 
ASP/ADHD sample (34.3 years) and the two NIA samples (33.3 and 34.5 years) fell 
between these extremes. There was a natural predominance of male subjects in the 
ASP/ADHD group (only males) and in the Asperger’s disorder group (7:3), while 
females were over-represented in the RLS group (14:1). The different recruitment 
channels and exclusion procedures further reduce the validity of inter-study 
comparison. 
 
The abilities and motivations of the subjects to communicate during the interview 
showed inter-group variability. Healthy controls and RLS patients communicated 
fluently and were very compliant in answering all questions posed by the clinician. 
This may have resulted in a lower stress level in these groups during the interview 
than in NIA, ADHD/ASP and Asperger patients, despite efforts to maintain a neutral, 
low-stress atmosphere for all subjects (see section 6.2.). Some of the Asperger’s 
disorder patients, in particular, may have felt that the naturalistic setting of a clinical 
interview was nevertheless challenging because of their qualitative difficulties in 
social interaction (American Psychiatric Association 2000). They did seem, however, 
to be able to regulate eye contact and topics of conversation when necessary, and none 
reported an unwillingness to continue the interview or any subsequent adverse effects 
of the interview. A more considerable problem was their unresponsiveness to the 
efforts of the clinician to restrict the interview to selected topics and to follow a 
standardized structure. The course of the conversation in the interview seemed to be 
affected by both individual differences and inter-group differences of study subjects. 
 
Another special group with respect to communication was the ASP/ADHD sample. 
Some of them found the clinical interview to be frustrating while simultaneously 
being interviewed frequently during the court-ordered mental examination, thus 
giving short, impulsive answers to the questions. Their status may also have affected 
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the reporting of their symptoms, and the retrospective evaluation of symptoms based 
on their capacity and motivation to remember may not have been very accurate. As 
most adult patients being evaluated for ADHD have not been psychiatrically 
evaluated as children, a recurrent problem is the retrospective diagnostics of 
childhood ADHD (Ward et al. 1993). ADHD symptoms fulfilling the diagnostic 
criteria must have been present in childhood in order to diagnose an adult patient with 
ADHD. In this study, however, a great amount of data from other informants and 
official papers had been collected during the court-ordered mental examination, which 
were available to confirm the history of ADHD.  
 
8.7. Limitations of the study 
 
The main limitations of this study include overlap of the subjects mainly due to a lack 
of controls fulfilling the study criteria (see section 5.6.), different recruitment 
channels for study patients and their  controls (see sections 5.2.-5.5. and  8.6.4.), less 
systematic exclusion procedures for controls (see sections 5.2.-5.5.) and their 
unconfirmed health status (see sections 8.3. and 8.6.4.), limited representativeness of 
the subject categories (see section 8.6.4.), study parameters affected by subjective 
reporting (see sections 6.4.-6.5.), methodological dilemma between standardization 
and maintaining the naturalistic character of the setting in controlled rest-activity 
assessment (see section 8.6.1.), poor generalizability of specific actometric findings 
(see section 8.6.2.), lack of reliability measures (see section 8.6.2.), application of 
BARS in populations, for which it is not validated (see section 8.6.3.),  non-controlled 
factors possibly affecting motor activity, such as intake of nicotine and caffeine  and 
thyreoid function (not controlled for in RLS patients and in most of the controls), 
subclinical affective and anxiety pathology (not systematically controlled for in 
healthy controls and NIA patients) and personality factors (not controlled for in 
healthy controls and NIA patients). 
 
9. CONCLUSIONS 
 
The results show abnormal rest-activity in each of the neuropsychiatric disorders of 
this study. Quantitatively, the activity is increased, and qualitatively, it is different 
from the rest-activity of healthy controls. Controlled rest-activity seems to be more 
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specific as a measure of abnormal motor function than diurnal activity in hyperactive 
disorders. Controlled rest-activity measured by actometry can be used as a diagnostic 
marker and a measure of symptom severity in NIA. The diagnosis and assessment of 
NIA has previously relied on a clinician’s subjective evaluation. More objective 
methods should be applied in clinical trials, which form the basis of treatment 
guidelines and reimbursement decisions concerning drug treatments. The motor 
component of NIA can be easily and objectively monitored in treatment trials and in 
clinical practice by measuring controlled rest-activity with non-invasive actometric 
monitors. 
 
Combining the quantitative and qualitative results in RLS with earlier findings 
(Montplaisir et al. 1998), the RLS patients are concluded to demonstrate a 
considerable amount of lower limb motor hyperactivity at rest, both awake and asleep, 
which is not accounted for by the PLM phenomenon. This apparently non-specific 
activity would most naturally be explained by the paresthesias and dysesthesias of the 
lower limbs causing an urge to move, an essential diagnostic feature of RLS. Motor 
restlessness, itself, is also an essential diagnostic feature of RLS (IRLSSG 1995). In 
the absence of reliable, objective assessment methods, the actometric recording of 
nocturnal lower limb rest-activity offers an option for measuring symptom severity 
and for supporting a diagnosis of RLS. The benefits of this method are 1. simple home 
recording with minimal disturbance of the subject, 2. good discriminative qualities, 3. 
an objective, quantitative measure of motor activity and 4. inclusion of the restless 
movements which are a response to subjective, sensory symptoms essential to the 
diagnosis. 
 
Considering the previous studies (Halperin et al. 1992, Reichenbach et al. 1992, 
Teicher 1995, Dane et al. 2000), the increased rest-activity in adult ASP patients with 
ADHD is an important objective sign of residual ADHD symptoms and a useful 
measure of symptom severity. The abnormal rest-activity of Asperger patients was 
here objectively demonstrated for the first time. The quantitative and qualitative 
findings suggest the importance of careful evaluation of motor abnormalities in 
Asperger’s disorder, which may be helpful in defining the subtype and  the severity of 
motor symptoms. The findings in ASP with ADHD and in Asperger’s syndrome 
suggest idiopathic akathisia in these developmental disorders, which may be 
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explained by the dopaminergic dysregulation in both ADHD (Lou et al. 1989, Lewy 
and Swanson 2001) and Asperger’s disorder (Jacobson et al. 1988, Ernst et al. 1997). 
The pre-existing akathisia-like activity in these disorders indicates special 
pharmacological consideration should be given when prescribing drugs which may 
induce akathisia since akathisia may aggravate the aggressive, dysphoric and 
hyperactive symptoms of Asperger’s disorder and ADHD. Besides idiopathic 
akathisia, this activity pattern may also represent a more common phenomenon of 
basal ganglia-generated stereotypic movements encountered in several 
neuropsychiatric disorders including ADHD, autism and akathisia (Tan et al. 1997).  
 
Measuring motor activity offers a narrow but objective window to assessment of 
symptom severity and pathophysiological mechanisms of neuropsychiatric disorders. 
Measuring rest-activity by ambulatory activity monitors provides a useful and 
naturalistic assessment method. The instrumental measurements, however, give 
limited information on symptom severity. The impact of motor symptoms on the 
patient’s daily life and functioning, which is of primary clinical importance, cannot be 
measured by actometry. Technical measurements also lack the aspect of subjective 
experience and suffering of the patient, which is fundamental in all psychiatric care. 
Combining this objective, quantitative assessment with the more traditional 
psychiatric evaluations will offer an integrative approach to meet the current needs of 
neuropsychiatric care and research. 
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